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ABSTRACT 
 
 
GENE REGULATION THROUGH ARTIFICIALLY INDUCED DNA  
 
CONFORMATIONAL CHANGES 
 
 
 
 
 
 
 
By 
 
David Bednarski 
 
May 2008 
 
 
 
Thesis supervised by Steven Firestine, Ph. D.  
 
 The conformation of DNA has been shown to play an important role in the 
regulation of gene expression.  A consequence of this finding is that agents that alter the 
conformation of DNA should also affect the regulation of gene expression.  To explore 
this, we used tethered-triple helix oligonucleotides (TFO) to bend DNA.  We show that 
the expression of a luciferase gene is regulated by the presence of an induced DNA bend.  
Bends occurring in the same orientation as RNA polymerase binding result in a 93% 
increase in expression.  In contrast, bends induced in that opposite direction resulted in a 
51% decrease in expression.  These results prompted us to investigate the synthesis of 
three small molecules with the potential to induce a sequence selective bend in DNA.  
These studies revealed that the compounds were able to induce a DNA bend counter to an 
intrinsic bend present in a target DNA fragment. 
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I. LITERATURE SURVEY 
Gene expression is a fundamental biological process in which DNA sequences are 
converted to RNA and proteins crucial to the life of an organism.  Cells regulate gene 
expression to control a multitude of functions from normal cell maintenance to apoptosis.  
Gene expression can be regulated at any step of the process, from transcription to protein 
modification.  Aberrant gene expression is the result of a loss of normal regulation and is 
linked to a number of diseases ranging from cancer to Alzheimer’s disease.1-5  The 
development of new mechanisms of artificial gene regulation will lead to the creation of 
pharmacological agents capable of treating a variety of diseases. 
A number of methods have been employed to establish artificial control over gene 
expression.  These methods have utilized a wide range of ligands, from DNA to proteins 
and small molecules.6-64  These methods seek to either inhibit or recruit the binding of 
proteins to DNA or mRNA to alter the expression of a target gene.  An under utilized 
method to establish artificial gene regulation is to alter the conformation of DNA, 
particularly upstream of a target gene.  The flexibility of DNA and the conformations that 
it can adopt, particularly DNA bends, play important roles in various processes including 
transcription.  Though DNA can be intrinsically bent and can be bent by the binding of 
various proteins, these methods are not acceptable pharmacological treatment methods.  
Such treatment methods require the bending of DNA through artificial means, including 
nucleic acids and small molecules. 
I.A. Artificial Gene Regulation 
There are a number of mechanisms that have been used to establish artificial 
control over gene expression including antisense oligonucleotides, RNAi, zinc finger 
1 
proteins, triple helix oligonucleotides, peptide nucleic acids, and small molecules. These 
methods will be individually discussed below.  
 
Antisense Oligonucleotides  
Gene expression has been modified through targeting mRNA with the intent of 
either blocking its translation or degrading it through enzymatic action, silencing the 
expression of its parent gene.  A number of oligonucleotides have been used to form 
duplexes with target mRNA to inhibit the translation of the mRNA and silence the 
expression of a gene.  These complementary oligonucleotides have included DNA, the 
oligonucleotide analogue PNA, LNA and PMO.6-10  DNA and PNA will be discussed in 
greater depth (see Triple Helix Oligonucleotides and Peptide Nucleic Acids sections). 
 LNA, locked nucleic acid, are oligonucleotide analogues of RNA.  The bases of 
LNA contain methylene linkages between the 2’ oxygen and the 4’ carbon of the ribose 
ring.  This linkage locks the 3’-carbon in the endo conformation, resulting in high-affinity 
binding and increased melting temperature.6-7  LNA complementary to target mRNA is 
able to form duplexes that activate RNase H, resulting in the degradation of mRNA and 
the silencing of the expression of a target gene. 
PMOs or phosphorodiamidate morpholino oligonucleotides are oligonucleotide 
analogues that display the standard nucleic acid bases.  The deoxyribose rings of DNA 
and the ribose rings of RNA are replaced with six-membered morpholine rings while the 
phosphate linkers were replaced with phosphorodiamidate groups.  The inclusion of the 
phosphorodiamidate groups eliminated the negative charge of the phosphate backbone 
under physiological conditions allowing PMOs to bind to their RNA targets without the 
2 
negative charge repulsion present in the formation of DNA/RNA and dsRNA duplexes.  
PMOs were targeted to 25-bp regions of mRNA to block the binding of the ribosomal 
intitiation complex, inhibiting the translation of mRNA.8-9  In addition, PMOs can 
interfere with the splicing of introns from pre-processed mRNA to alter the expression of 
a gene.8,10-11
 
RNA Interference 
Genes have been down regulated and completely silenced by interfering with the 
translation of mRNA through the formation of double-stranded RNA using a technique 
called RNA interference, RNAi.12  RNAi methods are derived from the native 
degradation of RNA through the formation of double stranded RNA.  These methods 
redirect this process to target the mRNA of a gene of interest.12-13  Double-stranded RNA, 
homologous to a target sequence of mRNA, is delivered to the nucleus of a cell (Fig. 1).  
Riobnuclease III cleaves these dsRNA strands into 21- and 22-nucleotide fragments 
called small interfering RNA, siRNA.  The generated siRNA bind to the target mRNA 
strands and create new RNA duplexes.  Like the dsRNA parent of the siRNA fragments, 
the mRNA/siRNA duplexes are degraded by a protein complex called Dicer, silencing 
the expression of the originating gene.  This method has been used to silence reporter 
genes in Drosophila and mammalian cell lines.12  RNAi was also used to produce high-
amylose potatoes by silencing two genes encoding for starch branching enzymes.13  
3 
Figure 1.  RNA interference occurs when dsRNA enters the nucleus of and is broken 
down into 21- and 22-nucleotide siRNA by ribonuclease III.  siRNA then bind to target 
mRNA creating siRNA/mRNA duplexes that are cleaved into small fragments by 
ribonuclease III, preventing translation of the mRNA. 
 
Zinc Finger Proteins 
 Protein-based systems have also been used to activate transcription.  These 
activation systems were composed of two main domains, a DNA binding domain 
responsible for binding to a specific DNA sequence and an activation domain that 
recruites a transcriptional complex.  These systems included both fusion proteins and 
independent proteins that activate transcription upon dimerization.  A system composed 
of DNA-binding domain proteins and activation domain proteins was used to activate 
transcription, both in vitro and in vivo, upon dimerization by a dimerization ligand.14  The 
proteins that have been used for targeting DNA sequences and for activating transcription 
are highly variable, though one of the most commonly used protein-based DNA-binding 
domains were zinc finger-proteins.15-16
 Zinc finger-proteins are composed of C2H2ZF domains, an α-helix packed against 
two anti-parallel β-strands with stability provided by the coordination of a zinc ion by the 
side chains of two cysteine and two histidine residues (Fig. 2).  Zinc finger proteins are 
able to bind to a variety of DNA sequences due to the variability of the DNA binding 
RNA 
fragment
ribonuclease III mRNA 
cytoplasm
 
nucleus  
dsRNA dsRNA siRNA siRNA/mRNA 
Dicer 
nuclear membrane 
cell membrane 
4 
region of the proteins.  The N-terminus residues of the zinc finger domain α-helix make 
contact with the major groove of DNA at a recognition triplet, which is customizable 
based on the amino acids of the particular domain.15-16  Unfortunately, zinc finger 
proteins cannot target all DNA sequences with equal efficiency; the zinc finger domain 
has difficulty targeting pyrimidines; cytosine and thymine. 
 
Figure 2.  Polydactyl zinc fingers bound to DNA.  The zinc fingers are blue, the DNA is 
orange and the zinc ions are green.  Zinc ions are coordinated by two cysteine and two 
Multiple zinc fingers domains have been linked to form polydactyl zinc finger 
histidine residues.  Figure from PDB 1A1L, ZIF268 zinc finger-DNA complex (GCAC 
SITE).17
 
 
proteins to target longer, more specific DNA targets (Fig. 2).  Polydactyl zinc finger-
proteins have been used as DNA-binding domains for a number of gene activation motifs 
with activation domain proteins such as TBP and variations of the herpes simplex virus 
VP16 activation domain.18-19  These fusion proteins were used to activate the expression 
5 
of oncogenic genes ErbB-2 and ErbB-3, angiogenic genes VEGF-A and CD144, 
apoptotic gene BAX, and γ-globin as a potential treatment for sickle cell anemia.15-16,20-21  
When conjugated to KRAB (Krüppel associated box), ERD, ERF repressor domain, or 
SID (mSIN3 interaction domain), zinc finger-proteins served as binding partners for 
repressor domains.19
 
Triple Helix Oligonucleotides 
f DNA that are able to bind in the major groove of DNA 
er TFO binding motif that a TFO can bind into duplex DNA is one with an 
antipar
 TFOs are single strands o
through hydrogen bonds with the purine members of DNA base pairs, though they can 
tolerate some pyrimidines in their binding region.  There are two modes for this hydrogen 
bonding to occur, parallel and antiparallel, dependent on the orientation of a TFO in the 
major groove.22-24  The purine-rich DNA strand serves as a reference when determining 
the binding mode of the TFO.  Parallel binding occurs when the TFO and a purine-rich 
DNA strand are in parallel, aligned with their 5’ and 3’ ends in the same orientation.  The 
hydrogen bonding that occurs in the parallel binding orientation is called Hoogsteen base 
pairing, or the pyrimidine motif (Fig. 3A).  TFO thymines bind to duplex adenines, while 
protonated cytosines of TFOs bind to duplex guanines.  Due to TFO cytosines requiring 
protonation to bind, triplex formation in parallel systems is pH dependent, favoring acidic 
environments. 
The oth
allel orientation.  A TFO and a purine-rich DNA strand of a DNA duplex run 
opposite of one another in terms of 5’-3’ directionality.  The hydrogen bonds formed 
between TFOs and antiparallel DNA are known as Reverse Hoogsteen or the purine 
6 
motif (Fig. 3B).  Reverse Hoogsteen base pairing is comprised of purines hydrogen 
bonding to purines; adenine binds to adenine and guanine binds to guanine.  The 
antiparallel orientation can also contain thymines of a TFO strand bound to the adenines 
of the purine-rich duplex DNA strand.25  Unlike regular Hoogsteen base pairing, Reverse 
Hoogsteen bonds do not have a pH requirement. 
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Figure 3.  (A) Hoogsteen base pairs used in the formation of DNA triplexes; thymine to a 
Watson-Crick base paired adenine and thymine and a protonated cytosine to a Watson-
Single TFOs have been used to both inhibit and activate transcription.  TFOs have 
been used as antigene inhibitors that bind to target DNA sequences to inhibit gene 
Crick base paired guanine and cytosine. (B) The Reverse Hoogsteen hydrogen bonding 
motif found in triplex DNA. 
 
  
7 
expression, most often blocking transcriptional initiation.26  The expression of c-myc 
genes, rat α1(I) genes and oncogenic Ets2 genes were inhibited by binding TFOs to their 
respective promoters.27-30  TFOs have been used to block specific DNA-protein 
interactions integral to transcriptional activation.  TFOs inhibited gene expression when 
bound to the binding sites of Sp1 and SPy transcriptional factors in the promoter regions 
of Ha-ras and c-Src genes.31-32  In addition to preventing transcriptional activation, TFOs 
were used to inhibit transcriptional elongation by arresting the progression of bacterial 
RNA polymerase in in vitro experiments through the binding of TFOs to sites within a 
gene sequence.33
 Transcription was also inhibited by TFOs that mediated genomic modifications.  
DNA-damaging agents, such as psoralen, were coupled to TFOs to achieve site-directed 
leotide activation domains.  TFOs were conjugated to hairpin DNA 
DNA damage.34  Psoralens intercalated cellular DNA to form monoadducts and double 
strand crosslinks upon activation by UV irradiation.35-36  TFO/psoralen conjugates have 
been used to selectively inactivate transcription in skin cells as a treatment for psorosis.35  
Duplex DNA was distorted upon formation of either monoadducts or crosslinks by 
psoralen.  These distortions are recognized and repaired by nuclear excision repair 
mechanisms that leads to strand breaks and recombination that eliminated and activated 
gene expression.36-37
 TFOs also activated transcription by acting as the DNA-binding domain for 
protein and oligonuc
that contained transcription factor binding sites.38  Transcriptional machinery will be 
recruited to the TFO/hairpin-DNA conjugate, when bound to DNA, initiating 
transcription. 
8 
 As guanine-rich oligonucleotides, TFO were prone to self-association into 
quartets and tetrads in physiological concentrations of potassium.34  TFOs were also 
ited
ucleic Acids
lim  by negative charge repulsion between the phosphate backbones of the duplex 
DNA and the TFO.  Replacement of three or four adjacent 2’-O-methyl sugars of the 
TFO backbone with 2’-O-aminoethyl riboses alleviates this repulsion and stabilizes the 
triplex.39
 
Peptide N  
PNAs are oligonucleotide analogues in which the sugar phosphate group is 
ed N-(2-aminoethyl)glycine unit (Fig. 4A).40-42  Peptide nucleic 
d to dsDNA by displacing the second strand of DNA (Fig. 4B).  A second 
strand 
 
 
replaced with a uncharg
acids have also been used to artificially regulate gene expression.  Unlike TFOs, PNAs 
were not limited by negative charge repulsion with the backbones of target DNA.  PNAs 
are uncharged under physiological conditions and are resistant to nucleases and proteases, 
making them a more stable alternative to TFOs for targeting transcription to alter 
transcription. 
PNA binds to DNA by forming both Watson-Crick and Hoogsteen base pairs.  
PNAs can bin
of PNA can bind to a PNA/DNA duplex to form a triplex.  The displaced DNA 
strand forms a single-stranded displacement loop (D-loop) recognized by RNA 
polymerase as an initiation site comparable to a strong promoter.43  PNAs have been 
targeted to sites where transcriptional activation was desired, such as upstream of γ-
globin genes to treat sickle cell anemia.40
9 
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hromosomal DNA, arresting transcription by inhibiting elongation.44  Antigene PNA 
was us
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5’ 
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with strand invasion 
Figure 4.  (A) PNA backbone consisting of uncharged N-(2-aminoethyl)glycine units 
linked by amide bonds.  (B) PNA binds to DNA forming triplexes that displace one 
strand of DNA forming a D-loop. 
 
Additionally, PNAs have been used to inhibit transcription.  PNAs were used in 
an antigene mechanism by binding to the ssDNA of open transcription complexes in 
c
ed to down regulate the mutant KRAS gene, with minimal effect to wild-type 
KRAS.41  Like TFOs, PNA has been used to block the binding sites of proteins required 
for gene activation.42  PNAs were also used to deliver DNA damaging agents, such as 
psoralen, to a particular sequence to induce DNA repair and silence a gene.36
While lacking the negative charge repulsion limitation of TFOs and other 
oligonucleotides, PNAs are limited in their ability to penetrate cell membranes.  
However, conjugations of PNA with cell penetrating peptides and nuclear
10 
peptides have been shown to ease the passage of PNA through cell and nuclear 
membranes.41,45
 
Small Molecules 
There are a number of small molecules that have been used to control gene 
xpression by targeting transcription by targeting transcriptional factors and DNA to 
ranscription.  These will be discussed below. 
 the interaction between 
p53 an
-rich DNA sequences.  This selectivity is largely due to 
the ster
e
inhibit or activate t
Small molecules have been used to inhibit transcription by targeting transcription 
factors.  An example of small molecules that functioned in this capacity was β-peptide 
peptidomimetics.  These peptide backbone analogues inhibited
d hMD2.46-47  The hMD2 protein negatively regulates p53, a tumor suppressor 
transcription factor.  β-peptide mimics of p53 bound to hMD2, allowing p53 to activate 
the transcription of genes that suppressed tumor growth and genes that promoted cell 
cycle arrest and apoptosis.  Similarly, small molecules were used to inhibit the interaction 
of p53 with MDM2, which is overexpressed in tumor cells and inhibited the activity of 
p53 to suppress tumor growth.47
Small molecules can also target DNA to affect transcription and artificially 
regulate gene expression.  Most compounds that target DNA bind to the minor groove 
and display a preference for AT
ic hindrance presented by the exocyclic amine of the guanine nucleotide in the 
minor groove. Polyamides netropsin and distamycin (Fig. 5) are naturally occurring 
antibiotics that served as the parent compounds of a series of sequence selective minor 
groove binding agents.  Netropsin and distamycin displayed a preference for binding to 
11 
AT-rich regions of DNA.  The binding energy of these compounds is derived from 
hydrogen bonds formed between the amide-NH groups of the compounds and the 
hydrogen bond acceptors in the minor groove.  Additional binding energy was provided 
by electrostatic interactions between the positively-charged amindine tails of the 
compounds and the negatively-charged phosphate oxygens of the DNA backbone.  
Binding affinity is also enhanced by the hydrophobic interactions between the aromatic 
rings of the compound and the carbons of the ribose ring of DNA. 
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Figure 5.  Polyamides netropsin and distamycin. 
 
Polyamides, represented by distamycin, were able to bind to the DNA minor 
groove in two different binding modes based upon the stoichiometry of binding either 1:1 
r 2:1.  The first binding mode, 1:1, consisted of a single distamycin molecule bound in 
the min
inor groove site (Fig. 6B).  The minor groove is 
widened to accommodate the binding of two molecules.  The binding of the first 
o
or groove of an AT-rich region of DNA (Fig. 6A).  The 1:1 binding motif is the 
predominant binding mode at lower concentrations of the antibiotic.  Distamycin can 
bind in either orientation (Fig. 6A).48
 At higher concentrations of distamycin the second binding mode, 2:1, becomes 
the prevalent binding motif.49  The 2:1 binding mode involved two distamycin molecules 
binding to the same AT-rich DNA m
12 
d cin lowers the binding energy for the second distamycin and increases the second 
distamycin’s rate of binding.
istamy
50  The 2:1 binding mode is stabilized by dipole-dipole 
interactions between the pyrrole rings and the amide bonds of the molecules.  In this 
binding mode each distamycin is bound to a single strand of DNA, preventing bifurcated 
hydrogen bonds, which in turn increased the selectivity of the duplex toward AT-rich 
sequences in the minor groove.  
A 
 
B 
 
 
Figure 6.  Two binding modes seen in NMR studies of distamycin-DNA binding.  The 
(A) 1:1 binding mode and (B) 2:1 binding mode, distamycin to DNA.  There are two 
orientations possible for the 2:1 binding mode, parallel and anti-parallel, both of which 
result in a widening of the minor groove.  Parallel binding has not been experimentally 
observed. 
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The 2:1 binding mode could occur in two different orientations; parallel and anti-
cin 
e 
to char
binding 
A 
 
 
parallel (Fig. 6B).  The parallel orientation involved the stacking of two distamy
molecules such that their positively-charged amidine tails lay in the same direction.  Du
ge-charge repulsion of the amidine tails, parallel 2:1 binding does not occur.  The 
anti-parallel 2:1 binding mode, however, has been experimentally observed and is the 
most common higher order structure formed.  In the antiparallel binding mode, the 
distamycin molecules were stacked with their positively-charged tails at opposite ends of 
the binding motif, such that there is no charge-charge interaction between them. 
The 2:1 binding mode of distamycin allows both strands of a DNA sequence to be 
targeted in the minor groove in a sequence selective manner.  Dervan used distamycin as 
a lead compound in the creation of sequence selective minor groove 
B 
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Figure 7. (A) Example of Dervan’s hairpin polyamide.52 (B)  Hairpin polyamide from A 
bound to the minor groove of the DNA.  DNA is shown from a perspective of looking at 
the base pairs from their edge, with circled H’s representing hydrogen bond donors while 
circles with two dots, lone pair electrons, represent hydrogen bond acceptors.52
14 
polyam
an aliphatic amino acid to create a hairpin polyamide (Fig. 7A).  The side-by-side binding 
hese polyamide chains, with each chain targeting one strand of DNA, allowed this 
stem to target all four base pair arrangements in any sequence (Fig. 7B). 
The hairpin polyamide system utilized three different heterocyclic systems to 
recognize DNA; pyrrole (Py), imidazole (Im) and hydroxypyrrole (Hp) (Fig. 8).  The N-
methylpyrroles of the lead compound, distamycin, could target the N3 of adenine and the 
O2 of thymine in a bifurcated fashion with the connecting amide-NH groups.  In the 2:1 
binding motif, where only a single strand of DNA would be targeted by the moiety, either 
adenine or thymine could be targeted by an N-methylpyrrole (Fig. 8).  N-methylpyrroles 
could also accommodate the O2 of cytosine, normally inaccessible in the 1:1 binding 
hymine or 
Recognition of guanine presented a problem due to the protrusion of the exocyclic 
incorporation of imidazoles (Im) into the molecule.  Imidazoles act as hydrogen bond 
acceptors to the exocyclic (Fig. 8B).  The ability to target guanine allowed for the 
creation of hairpin polyamides capable of distinguishing between GC and CG base pairs 
with a combination of pyrrole and imidazole; Im/Py could target GC, while Py/Im could 
ides.51  Dervan’s polyamide minor groove binders utilized various heterocycles 
linked by amide bonds.  These polyamides, called lexitropsins, bound to DNA in the anti-
parallel 2:1 binding mode.  Two lexitropsin molecules were then linked at one end with 
cytosine nucleotides. 
amine group into the minor groove.  Guanine targeting was accomplished by the 
of t
sy
motif due to steric hindrance of the exocyclic amine of guanine in the minor groove.  
Hairpin polyamides could therefore use N-methylpyrroles to target adenine, t
target CG base pairs. 
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Dervan’s hairpin polyamides also possessed the ability to distinguish between AT 
and TA base pairs.  While paired pyrroles could target both adenine and thymine, there 
was no distinction between AT and TA.  By pairing an N-methylpyrrole with a 3-
hydroxypyrrole (Hp) in a hairpin polyamide AT and TA could be differentiated and 
independently targeted.  N-methylpyrroles cause a shift in the hydrogen bonding scheme 
of a polyamide depending on whether the N3 of an adenine or the O2 of a thymine is 
targeted.  3-Hydroxypyrrole alleviated this shifting by displaying a preference for 
thymine due to the presence of the hydroxy group.   This hydroxy group also may 
hydrogen bond with the O2 of thymine (Fig. 8C).   Combinations of N-methylpyrrole 
and 3-hydroxypyrrole in hairpin polyamides allowed for the independent targeting of AT 
and TA base pairs, Py/Hp and Hp/Py, respectively. 
Figure 8.  Minor groove binding schemes of heterocycles used in Dervan’s polyamides 
Hp. 
in AT and GC base pairs; (A) pyrrole, Py, (B) imidazole, Im, and (C) 3-hydroxypyrrole, 
53-54
54
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 Hairpin polyamides are able to target AT, TA, GC and CG base pairs 
independently (Table I).  This allowed molecules to be created to specifically target any 
sequence in DNA.  In addition to N-methylpyrrole, 3-hydroxpyrrole and imidazole a 
number of other heterocycles have been placed into polyamide chains including thiazoles, 
furans, oxazoles and benzimidazoles, among many others.
 
indicates recognition and “–” indicates no recognition. 
54-55
Table I: The sequence recognition of hairpin polyamides by heterocylic pair, where “+” 
Pair AT TA GC CG 
Py/Hp + - - - 
Hp/Py - + - - 
 
Polyamides are the only class of small molecules capable of selectively targeting 
transcription in a sequence-specific manner.   Polyamides were used to block the 
preventing crucial protein-DNA interactions.   Polyamides were used in this fashion to 
block the binding of TFIIIA to inhibit the expression of the 5S ribosomal gene in vitro.
the binding sites of transcription factors such as LEF-1, Ets-1.56  The transcription of 
promoter regions.   Polyamides were also bound to the hypoxia response element to 
prevent the binding of hypoxi ed cto  red ce the expression of VEGF.60
The customizability of rget any sequence of DNA permitted 
polyamides to serve as the DNA-binding dom ain transcriptional 
Im/Py - - + - 
Py/Im - - - +  
any predetermined DNA sequence and have been used to both inhibit and activate 
56
binding sites of transcription factors to inhibit the expression of adjacent genes by 
56-60
57-
58  Gene expression was inhibited in other instances where polyamides were used to block 
other genes, bHLH and hTGF- β1, were inhibited by binding polyamides in the respective 
56,59
a-induc  fa r to u
 polyamides to ta
ains of dual-dom
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activators.56,61-62  The activation domains of these activator complexes included both 
peptide ligands and other small molecules.  Hairpin polyamides tethered to activating 
peptides derived from the herpes simplex virus VP16 activator, were used to stimulate 
promoter specific transcription.62  
Peptide-based activation domains were replaced with small molecules to create 
completely synthetic small molecule transcriptional activators.63-64  Hairpin polyamides 
fused to isoxazolidines mimics of activation domains, were used as artificial transcription 
factors (Fig. 9).63  Fusions of hairpin polyamides to a molecule called wrenchnolol 
initiated transcription in a sequence-specific manner.64
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Figure 9. The structures of (A) isoxazolidines and (B) wrenchnolol. 
 
I.B. DN
ses a level of flexibility critical to 
numerous cellular activities.  The flexibility of DNA is derived from the potential 
A Bending 
 One method which has not received much attention in the artificial regulation of 
gene expression is the role that DNA conformation plays in gene regulation.  The 
common structural perception of DNA is that it exists as a rigid, rod-like, double helix.  
DNA, however, is not a rigid molecule.  DNA posses
18 
deformability of its structure, specifically the structures and interactions of the nucleotide 
bases (Fig. 10).65-67  This flexibility is best described in terms of “inverse stiffness” and is 
expressed as a persistence length, the distance over which DNA is effectively linear.68-70  
The persistence length is dependent on both the rigidity of DNA and sequence-derived, 
intrinsic DNA curvature.  DNA fragments shorter than 150 base pairs are considered to 
have rigid, linear character, while DNA sequences longer than 150 base pairs possessed 
more flexibility and have slightly curved structures.69  The flexibility of DNA allow for 
ing from packaging 
in nucleosomes to transcription. 
protein interactions necessary for the various activities of DNA, rang
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Figure 10. Watson-Crick base pairs; adenine, A,  to thymine, T,  and guanine, G,  to 
cytosine, C. 
 
 The innate flexibility of DNA allows it to adopt various conformations, distorting 
it from the aforementioned rod-like structure.  These conformations range from simple 
bends to full loops.   These distortions are the result of the widening of one of the 
grooves of a DNA region and compressing the complementary groove on the opposite 
face of the double helix.  These alterations in groove width are introduced into a DNA 
sequence by one of two general mechanisms, either nucleotide sequence dependent 
intrinsic bends or bends facilitated by an external force, such as a protein, cation or 
drug.
N
O
N N
CH3
N N
H
H
71
69,72-75
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Intrinsic conformation changes are the result of DNA sequences that possess a 
higher level of flexibility than other sequences.  The most common examples of these 
sequences are AT-rich DNA sequences.73  These sequences are found throughout the 
genome and interact with a variety of proteins including transcriptional proteins.76-77  
of DNA are derived from steric interactions between base pairs of a 
particular sequence.  The best known example of an intrinsically bent DNA sequence is 
the A-tract.  A-tracts consist of a sequence of four to six adjacent adenine-thymine base 
pairs that naturally bends the DNA toward the minor groove. The magnitude of the bend 
is about 18° from linear DNA (as measured from the center of the helical axis) and is 
caused by widening of the major groove as a result of a combination of tilt and roll 
helical deformations between the adenine-thymine base pairs (Fig. 11).   These A-
tracts are found within the genome and have roles in various DNA processes, including 
replication and transcription, either by the curve that they possess or by serving as a 
binding site for proteins that bind to pre-bent DNA.67,72,81-85
Static bends 
72,74,78-80
Figure 11.  The helical parameters of DNA are influenced by the sequence of a region.  
base pairs as a result of steric interaction.  Tilt (A) results in a change in the short axis 
base pairs.  A twist (C) deformation results in adjacent base pairs twisting about the axis 
a base pair, resulting in a less planar base pair and widening of the major groove.  A 
this change is due to a bend in the short axis between the nucleotides. 
These are the basic helical deformations that can be caused by a base pair or between 
between base pairs, while a roll (B) results in a change along the long axis between two 
of a DNA strand in relation to one another.  A propeller twist (D) involves a twist within 
buckle (E) is a base pair deformation that also results in a less planar base pair; however 
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While DNA conformation is affected by the sequence of nucleotides, DNA 
conformation is also naturally altered by external forces, namely interactions with DNA-
bending proteins.  These proteins included those that are architectural in nature serving 
only to bend the DNA, and those which possess other major functions, in addition to 
bending DNA.  The methods by which these proteins bend DNA are varied, but can be 
divided into two basic classes (Fig. 12); proteins that contact bent DNA on the convex 
side of the bend, bending DNA away from their binding position, and proteins that 
 major groove and 
bent the DNA away from the protein. A number of proteins functioned by this method 
including transcriptional factors such as the eukaryotic TATA binding protein (TBP) 
(Fig. 12). 
The second class of DNA bending proteins, concave benders, functioned by 
bending DNA toward or around themselves.  Many of these concave benders 
electrostatically interact with the DNA.   Examples of proteins that bend DNA from the 
concave side of the bend included the eukaryotic histone octamer, the prokaryotic 
integration host factor (IHF) and the prokaryotic catabolite-activating protein (CAP) (Fig. 
12). 
 
contact the concave side of DNA bends, bending the DNA around itself.69,75
The first class of DNA bending proteins, known as convex benders, bent DNA 
through hydrophobic interactions between amino acids of the protein and base pairs in 
the minor groove of the DNA.  The presence of the amino acids in the minor groove, and 
the resulting interactions, widened the minor groove, compressed the
86
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Figure 12. Examples of DNA bending proteins. Protein that bends from the convex side 
of the induced bend TBP, A. Proteins that bend DNA from the concave side of the 
induced bend include nucleosome formation about a histone octamer, B; IHF, C; and 
CAP, D. 
 
I.C. DNA Bending and Transcription 
I.C.1. Potential mechanisms for the role of DNA bending in transcription  
The focus of this thesis is the crucial role DNA bending plays in transcriptional 
regulation.  Various studies have shown that DNA bending participates in transcription in 
two main capacities.  First, RNA polymerase causes DNA bending upon binding to the 
promoter sequence of a gene.  Second, the binding of transcription factors in the promoter 
region of a gene also results in bent DNA, although it is possible that the binding sites of 
some transcription factors are already pre-bent.  Pre-bent DNA sequences may function 
as a mechanism to attract the transcription factors to bind to their sites.67,85
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 While it is generally agreed that DNA bending upstream in the promoter region of 
a gene is important to the regulation of genetic expression, the mechanism of how 
bending regulates gene expression remains in question.77,85  There are two basic theories 
regarding the role played by DNA bends on gene regulation.  The first theory suggests 
that DNA bends function in an architectural capacity, bringing distally bound proteins 
into proximity with the RNA polymerase (Fig. 13A), while the second theory suggests 
that DNA bending facilitates DNA wrapping about RNA polymerase (Fig. 13B).  
 
A 
 
B 
 
Fig
Inte
ure 13. The two models of DNA bending and transcriptional regulation. (A) 
ractions between RNA polymerase and distally bound transcription factors brought 
into proximity by DNA bend and (B) DNA wrapping facilitated by DNA bending. 
 
The initiation of transcription requires the assembly of multiple protein 
complexes.  The proteins involved in these complexes may be bound at nonadjacent 
A sites and must be brought into contact for the formation of the transcriptal initiation 
complex.23,82-83,87-93  For example,  transcription factors TFIIA, TFIIB, TFIIC, TFIID 
DN
23 
(also known as TBP), TFIIE, TFIIF and TFIIH and RNA polymerase in eukaryotic 
systems all most interact to form the transcriptional complex.  The control of expression 
also involves interactions of the transcriptional complex and RNA polymerase with 
proteins bound upstream such as activators, enhancers and repressors.  Interactions 
between upstream and downstream proteins are facilitated through the distortion of the 
atural 
flexibil
83,94-96
96
intervening DNA helix, bringing the proteins of interest into proximity (Fig. 13A).  In the 
ase of longer intervening DNA sequences, greater than 500 base pairs, the nc
ity of the DNA will allow bending to occur and the proteins will be brought into 
the required proximity.  However, for shorter distances, DNA is more rigid and requires 
the binding of DNA-bending proteins to facilitate the formation of protein-protein 
interactions necessary for the completion of the transcription initiation complex.  Thus, 
DNA bending regulates transcription by facilitating the interaction of RNA polymerase 
and distally bound proteins. 
The second theory regarding the role of upstream DNA bending and gene 
regulation asserts that bending is required for wrapping DNA about RNA polymerase in 
both prokaryotic and eukaryotic transcriptional complexes.   DNA wrapping has 
been visualized by footprinting, DNA supercoiling experiments, microscopy and protein-
DNA crosslinking analysis.   DNA becomes wrapped around RNA polymerase upon its 
binding to the promoter region of a gene.  RNA polymerase comes into contact with 
DNA both upstream and downstream of the transcriptional start site (Fig. 13B).  DNA 
wrapping facilitates strand separation, required for transcription, by introducing torsional 
strain in the double helix. 
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Wrapping of DNA around RNA polymerase requires about 60 kJ/mol of energy to 
alter the conformation of DNA.96  The presence of other DNA bending proteins, such as 
TATA-
merase binding position, has an enormous effect on the 
transcri
in the 
experim
binding protein (TBP) in eukaryotic transcription complexes, lessens the cost of 
wrapping DNA around RNA polymerase.95,97  Upon binding, TBP induces an 80° bend 
toward the major groove of DNA prior to RNA polymerase DNA wrapping.  Pre-bent 
DNA lowering the cost of DNA wrapping is also seen in prokaryotic systems, where 
RNA polymerase binds to promoter regions that contain intrinsically bent DNA.83
While the exact role that DNA bends play in transcriptional regulation is 
unknown, their position, subsequent directionality and intensity are all important factors 
in the transcriptional regulation of a gene.  The orientation of a DNA bend, relative to the 
promoter and RNA poly
ption of a gene.  By changing the position of a facilitated bend, its location and 
orientation relative to a gene promoter is also changed.  The orientation of a facilitated 
bends, such as those induced by Sox2, may be the result of single nucleotide changes in 
the binding site consensus sequences of DNA bending transcription factors.93  Changing 
the orientation of a facilitated bend relative to a promoter will prevent optimal 
interactions between distally bound proteins and the transcription machinery resulting in 
decreased transcription levels.93,98  This phenomenon is explored later, 
ental validation of the role of DNA bending in transcription section. 
In addition to the position and orientation of a DNA bend, the degree of a DNA 
bend plays an important part in determining gene transcription levels.  TBP binds to and 
induces DNA bends in promoters that contain the TATA box consensus sequence, while 
the SRY-related Sox2 protein binds to HMG box sequences.  The bend induced by TBP 
25 
at these binding sites varies in intensity, ranging from 30° to 106°.99-100  Sox2 induces an 
83° bend in its binding site, while a mutation in the protein resulted in a bend angle of 
46°.93  These studies indicate that there is a direct correlation between bend angle and 
transcription.  In addition, these studies indicated that the presence of an optimal bend 
angle for transcription while bends that were too small or too large resulted in decreased 
transcription levels.93,99-100  The induction of a bend by TBP at the TATA box was 
described by a two state model in which transcription was not activated by TBP while a 
DNA b
I.C.2. Experimental validation of the role of DNA bending in transcription 
To analyze the role of protein-induced DNA bends in transcriptional regulation, a 
number of replacement studies were preformed.  In these studies, the binding sites of 
various DNA-bending proteins were replaced with either intrinsically bent DNA or 
binding sites for heterologous DNA-bending proteins.  Gartenberg and Crothers replaced 
the binding site for the DNA-bending protein CAP, located upstream of a lac promoter, 
with phased A-tracts in vitro.101  Transcription was up-regulated by the presence of the 
A-tract.  It was hypothesized that this up-regulation was due to the A-tract curve 
mimicking the bend induced by normal CAP binding.  When the curvature of the A-tract 
was directed towards the opposite face of the helix, in opposition to a normal CAP-
induced DNA bend, transcription was inhibited indicating that the orientation of a DNA 
bend upstream of a gene could influence the expression levels of that gene.  Similar 
studies had been performed on the lac operon in vivo by replacing the binding site for 
end was only slightly induced, but upon the induction of an 80° DNA bend, 
transcription became activated, demonstrating that transcriptional activation requires the 
induction of a DNA bend of a certain magnitude.100
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DNA-bending CAP with various A-tract sequence combinations either in-phase (bend 
occurs 
ve orientation of the A-tract bend suggests that 
in the same direction as CAP) or out-of-phase (opposite direction compared to 
CAP bending) with the start of the target gene.102  The results were the same as those 
seen by Gartenberg and Crothers in their in vitro experiments; the A-tracts phased as the 
natural CAP binding site up regulated the expression of the encoded gene, while the A-
tracts bending the DNA out-of-phase with the normal CAP bend displayed down 
regulated gene expression.  These studies also demonstrated the role of DNA bending and 
its importance in the regulation of genetic transcription through the effects of changing 
the phase of the bend.  They illustrate the importance of the three-dimensional orientation 
of DNA bends its role in gene regulation. 
The down-regulation and total inhibition of expression demonstrated by out-of-
phase DNA bends can be explained by both theories on the roles of DNA bending in 
transcription.  In terms of DNA wrapping, bending the DNA in the opposite direction of 
that which facilitates transcription prevents the DNA from interacting with the RNA 
polymerase in a manner to induce DNA wrapping.  Bending the DNA opposite that of 
transcriptional activation would also prevent distally bound proteins from being brought 
into proximity for interaction at the promoter.   
Later work revealed that A-tracts, while intrinsically bent, were also a binding site 
for the sigma subunit of RNA polymerase, bringing into question the actual effects of the 
intrinsic bend of an A-tract on transcription in both in vitro and in vivo environments.103  
The authors suggested that the effects on transcription were due to the placement of a 
new RNA polymerase binding site into the promoter.  However, the fact that the activity 
of promoter was dependent upon the relati
27 
other factors may be involved besides the inclusion of a new RNA polymerase binding 
site. 
 
 
Figure 14. Protein replacement assay.  The naturally occurring CAP binding site (CAP 
bs) was replaced with a DNA bending protein binding site (DBP bs).  CAP both bends 
DNA and interacts with RNA polymerase (RNA pol) resulting in transcription.  Orienting 
the DBP bs as the CAP bs resulted in transcription through the bending action of the 
DNA bending protein (DBP) without RNA pol interactions.  Orienting the DNA bs such 
that the DBP induced DNA bend was opposite that of CAP resulted in no transcription. 
 
The ability of an A-tract to function as an RNA polymerase binding site 
eliminated its use as an accurate tool to evaluate the role of DNA bending in 
transcription.  Other approaches were required to determine the function of DNA bends 
in transcriptional regulation.  A simple approach involved replacing the binding site of a 
native DNA-bending protein with the binding site of a DNA-bending protein foreign to 
the system (Fig. 14).  Perez-Martin and Espinosa used this method to determine the 
importance of a DNA bend induced by CAP in transcription in vivo.104  They replaced the 
native CAP binding site in the fur operon with the binding site of an unrelated repressor 
protein, RepA.  RepA is a known DNA-bending protein and heterologous to CAP, 
28 
preventing CAP from interacting with both the RepA binding site and RNA polymerase.  
Like the A-tract replacement experiments, placing the RepA site in the same phase as a 
naturally occurring CAP binding site increased the interaction of RNA polymerase with 
the promoter and transcription was initiated.  Conversely, when the RepA site was phased 
opposit
ins were 
inserted
e to the normal CAP binding site orientation transcription was hindered. 
Déthiollaz et al carried out a similar experiment, replacing the native CAP 
binding site in a malT promoter with a binding site for an IHF protein in in vivo 
experiments.105  Unlike CAP, the heterologous IHF protein did not interact with RNA 
polymerase, limiting any effects on gene expression solely to the IHF-induced DNA 
bend.  Transcription was activated in the altered malT promoter when IHF was bound to 
its binding site oriented as the original CAP binding site.  These protein replacement 
studies demonstrated the importance of the DNA conformation in transcription, 
specifically the role of DNA bend orientation in relation to the start of a gene. 
  The role of DNA bending in transcription has also been analyzed through the 
insertion of a DNA-bending protein binding site into a gene promoter, between the 
binding sites of transcriptional factors whose interaction is required for transcriptional 
activation (Fig. 15).23  The binding sites of YY1, LEF-1 and Sp1 proteins were evaluated 
for their abilities to modulate transcription.  The binding sites for these prote
 between eukaryotic transcriptional complex binding regions, where the RNA 
polymerase bound, and activator/enhancer regions, which increase the rate of 
transcription.  All of the proteins were able to induce DNA bends at their inserted binding 
sites.  The bends induced by YY1, LEF-1 and Sp1 facilitated protein-protein interactions 
between the transcriptional binding complex and proteins at the activator or enhancer 
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regions, allowing transcription to proceed.  Transcription only occurred when the induced 
bend was properly oriented, allowing for interaction between proteins bound to the 
transcriptional complex binding site and to the activator/enhancer binding site.  Improper 
phasing of the induced bend inhibited transcription by preventing the required 
interactions of the distally located proteins in the promoter region. 
The importance of the orientation of a DNA bend relative to the transcriptional 
start site of a gene and its role in gene expression was also demonstrated by altering the 
flexibility of sequence of DNA upstream of a gene.  Scaffadi’s group created various 
mutants of the DNA bending protein Sox2 and its respective binding site, located 
upstream of an Fgf4 gene.93  These mutations showed a correlation between the 
flexibility of DNA and gene expression in vivo.  When a mutation granted DNA greater 
levels of flexibility the level of transcription of the Fgf4 gene increased.  Conversely, 
decreased flexibility resulted in a loss of transcription and gene expression. 
 
transcription factor binding region. 
Figure 15.  DNA bending protein binding site insertion into RNA polymerase 
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I.D. Artificial DNA Bending 
The ability of DNA bending to either up regulate or down regulate transcription 
indicated that it could serve as a potential mechanism to artificially regulate genetic 
expression to treat transcription related diseases.  Targeting DNA as a means to regulate 
transcription has advantages over other methods of artificial gene modulation.106-107  As 
opposed to targeting gene products such as mRNA or proteins, which exist in abundance 
in every cell, targeting DNA is attractive due to there being only a single target per cell.  
Targeting DNA bending has an additional advantage that it does not require competition 
with the potent binding of transcription factors.  Only the overall shape of the 
transcriptional complex is important.  On the other hand, targeting a specific sequence 
within genomic DNA becomes difficult with the potential existence of multiple binding 
 
  Within cells, DNA bending is present in the forms 
of intrinsically bent DNA sequences and the binding of DNA bending proteins.  These 
methods would be impractical as mechanisms to artificially induce DNA bends.   
Sequence-dependent DNA bending would require alteration of the genomic DNA 
sequences, which would require the delivery and integration of a modified gene into the 
genome.  Using DNA-bending proteins would be less invasive, but their use has two 
major drawbacks.  First, the large size and multiple charges of many proteins make 
transport into the cell and nucleus difficult. Secondly, a protein would need to be 
engineered to target a specific sequence of DNA and retain its DNA bending ability. 
sites, making sequence specificity a priority in designing DNA binding agents.   
How does one induce a DNA bend?
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DNA bends have been artificially induced with non-protein ligands.  The 
mechanisms these moieties use to induce bends fall into one of two opposing categories; 
pull benders or push benders (Fig. 16). 
Tethered-triple helix-forming oligonucleotides, TFOs, are the quintessential 
example of pull-bending DNA ligands.  Tethered-TFOs are comprised of two single-
stranded, triple-helix forming DNA arms connected by a variable length molecular tether 
that does not interact with DNA.75,108-109 The utilization of tethered-TFOs in DNA 
Pull benders are composed of two DNA binding regions linked together with a 
molecular tether.  The only way that the two DNA binding regions can simulatenously 
bind to DNA is if the DNA bends.  Push benders bind to DNA and widened one of the 
grooves of DNA, resulting in the DNA being pushed away from the moiety and bending 
away from the bound ligand.  
 
Figure 16.  These are the general pull and push bending mechanisms.   A pull bender is 
an agent with two, tethered DNA binding regions that, once bound, pull and hold DNA 
into a bent conformation.  A push bender acts by binding into a DNA groove and 
widening it, pushing the walls of the groove away from the agent and bending the DNA 
away from the compound. 
 
dsDNA 
PUSH BENDING 
PULL BENDING 
tether 
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bending strategies has been investigated using both parallel and antiparallel systems of 
triplex formation.75,108-111  Both binding strategies used the same basic configuration; two 
TFOs, targeted to sites located one helical turn apart on duplex DNA, linked together by 
a linear molecular tether (Fig. 17).  The tethered-TFOs bound to duplex DNA and 
restricted the movement of the duplex DNA, holding it in a bent conformation. 
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 (A) The general structure of a tethered TFO, where the single stranded DNA, 
sDNA, can run either 5’ to 3’ or 3’ to 5’. (B) The linker subunits propylene glyco
hosphodiester, Pg, and triethylene glycol phosphodiester, Tg, utilized by Akiyama an
ogan. (C) Bending of a DNA duplex by a TFO. 
 
Akiyama and Hogan focused on tethered-TFO systems that utilized a variety of 
molecular linkers which varied in length, from 18 to 44 rotatable bonds, to conn
Figure 17.
s l 
p d 
H
ect a pair 
of antiparallel binding TFOs that were stabilized by T•AT and G•GC Reverse Hoogsteen 
base pairs.107,109-110  The antiparallel orientation was selected due to its ability to form 
stable triplexes under neutral conditions.  A variety of linkers were tested based on the 
33 
hypothesis that linkers with 25 or more ro ble bonds would not bend DNA, while a 
table bonds would induce a DNA bend once the tethered-TFO 
111  
Akiyama and Hogan established a number of conclusions based on their work 
with tethered-TFOs.108-110  They noted that the bends induced by the tethered-TFOs were 
toward the minor groove of the DNA and reasoned that this bend directionality explained 
to induce a bend in the DNA of around 60° with a tethered-
TFO was less than they had projected.   Akiyama and Hogan discerned that the sequence 
of the region of DNA spanning between the TFO binding sites affected the magnitude of 
the induced bend with AT-rich regions bending the most; though they claimed no relation 
to intrinsic bending.  They also demonstrated that shortening the length of the tethered-
 tethered-TFO with the shortest linker, 
three propylene glycol phosphodiester units with a total of 18 rotatable bonds, bound to 
duplex DNA with an AT-rich region between the TFO binding sites was able to induce a 
bend of about 60° in the duplex structure.  They demonstrated that a slight DNA bend 
was detected when tethered-TFOs with linkers comprised of 30 and 33 rotatable bonds, 
while linkers longer of this length were computationally projected to not possess the 
ability to bend DNA.111  Akiyama and Hogan reasoned that these linkers were not fully 
extended as expected, with probable gauche conformations in their linear structures, as 
opposed to the expected anti- conformations.  Suprisingly, unlinked TFOs were also 
reported to induce slight bends in duplex DNA targets, though no explanation as to why 
this occurred was given. 
tata
linker shorter than 25 rota
was bound.
why the free energy required 
TFO linker resulted in a direct effect on the magnitude of the induced DNA bend; the 
shorter the linker the greater the induced bend.  A
34 
The second category of DNA bending agents was the push benders.  Push bending 
is the result of introducing steric bulk into the minor groove of DNA such that the groove 
widens and the DNA bends away from the molecule.  Examples of such compounds 
include ecteinascidin-743 (ET-743) and calicheamicin (Fig. 18). 
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Figure 18.  Ecteinascidin-743, ET-743, and calicheamicin-ζ I. 
 
ET-743 is a natural product possessing potent antitumor activity, specifically 
against soft tissue sarcomas and advanced breast cancer.
1
the DNA to bend away from the molecule toward the major 
groove
to the minor groove of 
DNA and an enediyne region that is responsible for cleaving DNA upon binding.  In 
order to bind to the minor groove of the DNA calicheamicin requires that the groove 
112-114  ET-743 covalently 
attaches to DNA via the exocyclic N2 position of guanine.  ET-743 binds to DNA triplets 
with central guanine nucleotides, 5’- purine-G-C-3’ and 5’-pyrridine-G-G-3’.115-116  Once 
bound in the minor groove, ET-743 protrudes perpendicularly from its binding site (Fig. 
19).  The bulk of projecting molecule exerts steric force on the walls of the minor groove, 
widening it and causing 
. 
Calicheamicin (Fig. 18) is an antibiotic and tumoricidal agent belonging to the 
carbohydrate class of DNA binding compounds.117-119  Calicheamicin possesses both an 
aryltetrasaccharide tail responsible for binding the compound 
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widen to accommodate the bulk of the enediyne region of the molecule.119  This widening 
of the minor groove corresponds to a compression of the major groove on the opposite 
face of the DNA. 
 
Figure 19. ET-743 bound in the DNA minor groove. 
 
II. STAT
 
EMENT OF THE PROBLEM AND OVERVIEW OF EXPERIMENTAL 
APPRO
tential treatment of a number of diseases including cancer,1-3,120 
cardiovascular diseases121 and sickle cell anemia.122-123
ACH 
A number of diseases have aberrant gene expression.2-4,120-123  Thus, methods to 
artificially regulate gene expression would be a tremendous benefit.  The long term goal 
of the projects presented here is to create sequence specific DNA bending agents to 
artificially regulate genetic expression (Fig. 20).  These agents will induce a bend 
upstream of the promoter region of a gene resulting in either up-regulation or down-
regulation of expression.  The ability to artificially control the expression of a gene would 
allow for the po
36 
Transcription Factor
Binding Site 
DNA Bending Agent
Binding Site 
Figure 20. Regulation of transcription using an artificial DNA bending agent.  Induction 
of a bend with an artificial DNA-bending agent similar to that of a DNA-bending protein 
gulation of transcription.  Bending 
d result in an “out-of-phase” DNA 
end and a down regulation in transcription. 
Previous studies showed that both intrinsic DNA bends and bends induced by 
 
eterminate for gene regulation.23,93,101-105  
When by a 
ben
g a molecule which contains two DNA-
binding domains.  The only way in which the two domains can bind to DNA is if the 
DNA bends.  Push bending is accomplished through the widening of a DNA groove with 
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will result in an “in-phase” DNA bend and an up re
NA contrary to that of DNA bending protein woulD
b
 
DNA binding proteins effected transcription levels with the orientation of the bend
relative to the start of a gene being a critical d
the bend was oriented analogous to that caused naturally occurring 
transcription factor or RNA polymerase, an orientation known as an in-phase bend, a 
gene would be up regulated or activated.23,101-105  Conversely, an out-of-phase DNA bend, 
oriented in the opposite direction, resulted in the down regulation or silencing of gene 
expression.23,93,102,104  
How can one bend DNA?  There are two general methods to artificially bend 
DNA, namely pulling DNA into a bent conformation or pushing it into t 
conformation.  Pull bending is accomplished usin
IN-PHASE OUT-OF-PHASE 
RNA 
Pol 
Transcription 
Factor 
RNA 
Pol
DNA Bending
Agent 
DNA Bending Agent Binding of transcription factor 
activates transcription  
Binding of DNA bending agent
in the same phase as transcription 
factor activates transcription  
Binding of DNA bending agent
opposite to transcription factor, 
down regulates transcription 
a DNA binding agent.  This results in DNA bending away from the bound moiety.  The 
work presented in this thesis is divided into two main projects, with each project 
examining one of the two methods to artificially bend DNA.  The first project focuses on 
the artificial regulation of gene expression through DNA bends induced by tethered-
TFOs.  The second project involves the synthesis and investigation of a small, sequence 
selective, minor groove binding agent that function as a push bender through the 
introduction of bulk into the minor groove of a DNA target sequence.  
The first project will address the hypothesis that a non-protein moiety could 
regulate gene expression through the induction of DNA bending.  This project is essential 
in the development of artificial gene regulating agents as it will either validate or refute 
the concept that DNA bending alone could influence gene expression and that this 
influence could be achieved through artificial means.   We will use Akiyama and 
Hogan’s tethered-TFO system to artificially induce DNA bending in a synthetic 
promoter/gene system.   After bending of the target sequence is verified, we will 
examine the effects of bending on the expression of our target gene.  The orientation of 
the bend will be varied and we anticipate that proper orientation of the induced DNA 
bends will result in either the activation or repression of the target gene (Fig. 21). The 
above hypothesis is supported by previous studies utilizing intrinsically bent DNA and 
DNA-bending proteins to study the relationship between DNA bending and gene 
expression.
 
II.A. Project 1: Tethered-TFOs and Gene Expression 
108-110
23,93,101,104-105
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A 
 
 
B 
 
 
Figure 21. (A) Tethered-TFO bending DNA in-phase with a gene, causing the activation 
   
The sequence of the oligonucleotides and tethered-TFOs used in this study are 
shown in figure 22.  The tethered-TFO that induced the greatest DNA bend in Akiyama 
and Hogan’s experiments, labeled in our studies as the short tethered-TFO (STFO), will 
be used as the positive control.108-110  The negative control in our research will be the 
tethered-TFO that was previously shown to display no DNA bending ability; we have 
dubbed this moiety the long tethered-TFO (LTFO).  The negative control will be used to 
verify that any effects seen in our experiments will be due to DNA bending and not the 
binding of the tethered-TFO to the DNA targets.  We will also utilize “broken” versions 
of these tethered-TFOs (bSTFO, bLTFO) where the molecular tether and one TFO region 
will be separated from the other TFO (Fig. 22).  These broken variants of the tethered-
TFOs will be used to verify that any affects on gene expression will be due to DNA 
bending and not the formation of DNA triplexes. 
of transcription. (B) Tethered-TFO bending DNA out-of-phase with a gene resulting in 
the repression of transcription. 
 
RNA Pol 
RNA Pol 
Upstream 
Interacts with 
 
RNA Pol No Upstream 
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TFS
L
O:  5’-GGTGGGGTGGGTGGG-PgPgPg-GGGTGGGTGGGGTGG-3’ 
TFO:  5’-GGTGGGGTGGGTGGG-TgTgTgTg-GGGTGGGTGGGGTGG-3’ 
STFO: 5’-GGTGGGGTGGGTGGG-3’ and 5’-PgPgPg-GGGTGGGTGGGGTGG-3’ 
bLTFO: 5’-GGTGGGGTGGGTGGG-3’ and 5’-TgTgTgTg-GGGTGGGTGGGGTGG-3’ 
 
Figure 22. The tethered-TFOs that we will use in this project.  The short tethered-TFO, 
STFO, that will bend DNA and the long tethered-TFO, LTFO, which will serve as the 
negative control tethered-TFO com from Akiyama and Hogan.  The broken variants will 
be called bSTFO and bLTFO.  Pg represents a propylene glycol phosphodiester unit and 
Tg represents a triethylene glycol phosphodiester unit; see Fig. 6 for structures. 
 
Before testing the ability of tethered-TFOs to regulate gene expression, we will 
first verify that the target tethered-TFO binding sequence can be bent by STFO and not
 analysis.  DNA fragments containing the most flexible 
tethered
ression levels and, if so, determine the 
role that the phase of a bend has on artificial regulation. 
b
 
any of the other TFOs; LTFO, bSTFO and bLTFO.  Gel mobility shift assays will be used 
 tethered-TFO induced bendfor
-TFO target sequence used by Akiyama and Hogan will be used in these 
assays.108-109 After establishing the bending ability of our tethered-TFOs, we will then 
investigate the effects of the bends will have on gene expression when the bends are 
induced in varied orientations upstream of a luciferase gene. 
A series of plasmids containing the tethered-TFO target sequence used by 
Akiyama and Hogan will be positioned upstream of a promoter region and a luciferase 
gene (Fig. 23).108-109  By varying the distance between the tethered-TFO target sequence 
and the transcriptional start site of the luciferase gene, the orientation, or phase, of the 
induced bend relative to the gene will change as well.  TFO:DNA complexes will be 
subjected to an in vitro transcription/translation system.  The expressed luciferase protein 
will then be quantified through Western blot analysis.  We will determine whether the 
induced DNA bends have an effect on gene exp
40 
A 
 
          5’-GGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGG-3’ 
          3’-CCTCCCCTCCCTCCCGCGGCCGCGCCCTCCCTCCCCTCC-5’ 
 
B 
 
Figure 23. (A) The target sequence for these tethered-TFOs.  The triplex target regions 
re highlighted in gray, while the center of the induced bend is underlined. (B) Region of a
interest in plasm
Tethered-TFO Target Region Promoter Luciferase Gene 
Start Site of Transcription Variable Length Region For Phasing Bend 
id series containing the tethered-TFO target, the variable length region to 
phase t
igned to widen the minor groove 
of a DNA target through steric interactions between the walls of the minor groove and a 
he induced DNA bend, the promoter region and the start of the luciferase gene. 
 
We expect to learn that artificially induced DNA bends can effect gene expression 
and that the phase of the bend plays and important role in gene expression.  This project 
will serve to validate or refute the use of artificially induced DNA bends to regulate 
genetic expression. 
 
II.B. Project 2: A Sequence Selective Push Bender 
A series of small molecules that will function as sequence selective DNA push 
benders will be created in the second project.  While tethered-TFOs pull DNA into bent 
conformations that can artificially regulate the expression of a gene, proving the concept 
of artificial gene regulation through induced DNA bends, they are poor pharmaceutical 
candidates due to their size and the difficulties in the formation of DNA triplexes in 
vivo.124  Artificial gene regulation accomplished by a small molecule capable of passing 
through membrane barriers, selectively binding to a specific DNA target sequence and 
inducing a bend at that site upon binding would be ideal. 
Our proposed push bending compounds were des
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bulky moiety introduced by the binding of our compounds.  This bending mechanism will 
to create sequence 
ective push bending molecules. 
 
be coupled to a sequence specific, minor groove binding region 
sel
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Figure 24. (A) The lead compound, netropsin. (B) The structures of the netropsin 
labeled. 
hesize and evaluate a series of compounds that will act as sequence 
lective DNA push bending agents (Fig. 24).  Our compounds (1, 2 and 3) were modeled 
after the mechanisms of push benders such as ET-743 and calicheamicin, which 
introduce a bulky functional group in the minor groove of DNA forcing the groove to 
widen and bend the DNA.  Our compounds will couple a DNA binding region modeled 
after netropsin to a bulky region that will widen minor grooves upon binding.  These 
analogues consisted of three main regions; a DNA minor groove binding region, a 
phosphate binding region and a bulky moiety. 
 The minor groove binding region of our compounds was modeled after the amide-
linked, dual N-methylpyrrole binding region of netropsin.  This region should direct 
binding to AT-rich sequences based upon its similarity to netropsin.  A phenyl-bearing 
thiazole ring was substituted for the C-terminal N-methylpyrrole, and was oriented with 
the thiazole sulfur directed toward the minor groove-binding edge of the structure.  This 
 
analogues, 1, 2 and 3. The DNA minor groove binding region and phenyl bulk are 
 
We will synt
se
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substitution was done to ease the synthesis of our target compounds and to maintain the 
AT-rich DNA sequence binding preference of netropsin.55
The second region common to all of our compounds was the phosphate binding 
on located at the C-terminus of the structures.  Although netropsin possessed a C-
terminal amidine, we opted to use a single dimethylaminopropyl arm.  The 
dimethylaminopropyl arm was one methylene unit longer than the amidine arms of 
netropsin, granting the chain greater flexibility and greater freedom of movement to 
interact with DNA backbone phosphates once our compounds were bound to the mino  
an in the construction of various polyamide minor groove binders.125  The 
substitu
126-127
lecular modeling, by Dr. Steven Firestine 
regi
r
groove.  The dimethylaminopropyl arm used in our compounds had been previously used 
y Dervb
tion of a dimethylpropylamide tail for the amidine of the model compound will 
result in a decreased basicity which will enhance transport into the cell should these 
agents bend DNA as hoped.
The bulky moiety that our compounds will introduce into the minor groove of 
their DNA binding sites was a phenyl ring attached to the 4-position of the thiazole ring 
of the DNA minor groove binding region of the structures.  The phenyl ring will 
sterically interact with the walls of the minor groove, widening it, pushing the DNA into 
a bend away from the bound compounds.  Mo
with Molecular Operating Environment (MOE), shows that this phenyl ring will be 
projected perpendicularly from the minor groove binding region, maximizing steric 
interactions within the groove (Fig. 25). 
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A B 
  
Figure 25.  (A) Netropsin bound in the minor groove of DNA (1DNE from PDB). (B) 
Compound 1 modeled in the minor groove of DNA using MOE. 
 
The N-terminal guanidine arm bound to N-methylpyrrole of the lead compound 
netropsin was replaced by three different functional groups including a proton 
(compo
nterested in examining whether the inclusion of 
two potential DNA bending groups would enhance DNA bending.  Finally, a formamide 
was placed at the 4-position of the N-methylpyrrole in compound 3 in an effort to 
und 1), a tert-butoxycarbonylamino group (compound 2), and a formamide group 
(compound 3).  The single proton at this position in compound 1 should provide insight 
into the role that this position plays in the binding of our compounds to the minor groove 
of the DNA by removing the hydrogen binding and phosphate backbone interactions 
from this location.  Conversely, compound 2 possessed the largest functional group at the 
4-position of the N-methylpyrrole; a tert-butoxycarbonylamino group.  Previous, 
unpublished work from our laboratory had shown that the t-butyl group could alter the 
conformation of DNA.  Thus, we were i
44 
enhance binding affinity by incl g an additional hydrogen bond donor from the –NH 
of the amide bond of the formamide.48,51
 After synthesizing our compounds, they will be evaluated for their DNA binding 
ability, sequence binding preference and their ability to bend DNA.  An ethidium 
displacement assay will be used to determine binding ability and sequence preference.  
We expect our compounds to maintain the AT-rich sequence preference displayed by the 
lead compound, netropsin.  We also expect that the various analogues will possess 
different binding affinities, with the formyl-capped compound 3 having the greatest 
binding affinity.  FRET analysis will be used to determine what effect, if any, our 
studies
udin
compounds have on the conformation of a DNA target.  We expect to see a level of 
onformational distortion in DNA targets with the preferred DNA target sequence.  These c
 will provide important information to the future development of small, sequence 
selective DNA bending agents to artificially control the expression levels of target genes. 
 
 
III. RESULTS 
III.A. Project 1: Tethered-TFOs and Gene Expression 
III.A.1. Construction of Required Materials 
To investigate the role DNA bending played in gene expression, we utilized the 
tethered-TFO system described by Akiyama and Hogan.108-110  This system required two 
major components, namely a series of plasmids (pBLP) containing the target sequence 
for the tethered-TFOs and the tethered-TFOs with varied linker regions. 
45 
III.A.2. Construction of pBLP Plasmids  
The plasmid series pBLP was constructed through the insertion of 
lative to the start of the gene.  Assuming that our plasmids adopt the most common 
rm of DNA, B-DNA, each turn of the helix contains 10.5 base pairs.  The pBLP  
tween the center of the DNA bend and the 
transcriptional start of a luciferase gene by 3 base pair increments, ranging from 77 to 86 
d in relation to the luciferase 
ifference between the different phases can 
be calc
oligonucleotides into a series of vectors derived from pBR322.  The four plasmids of the 
pBLP series included two main sequence regions; a binding site for our tethered-TFOs 
spaced at various distances from a promoter sequence and a luciferase reporter gene.  
With the necessary fragments, we constructed four plasmids; pBLP77, pBLP80, pBLP83, 
and pBLP86.  The nomenclature used for our plasmid series was derived from the 
location of the bend relative to the start of the luciferase gene.    We constructed the 
pBLP plasmid series in a stepwise fashion (Fig. 26). 
 The purpose of the pBLP plasmid series was to position a luciferase gene at 
varying distances from the center of a target site for a tethered-TFO at which a DNA 
bend would be induced.  The helical nature of DNA means that varying the distance 
between two points on a strand of DNA results in a different orientation of the bend 
re
fo
plasmid series varied the distance be
base pairs.  This created four different phases of the ben
gene (Fig. 27A).  At 10.5 base pairs per turn d
ulated in terms of degrees (Fig. 27B). 
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  (A) Stepwise diagram of the creation of the pBLP plasmid series.  (B) The 
sequences of plasmids pBLP77, pBLP80, pBLP83 and pBLP86.  The tethered-TFO 
the center of the bend is highlighted in red. The malT 
promoter is under lined with the -10 region highlighted in gray and the -35 region is 
arts at the +1 position, highlighted in green. 
Figure 26.
binding sites are red, with 
highlighted in yellow. The luciferase gene st
47 
A 
 
B 
Difference in Position in Degrees 
Position 77 80 83 86 
77 - 102.86° 154.28° 51.42° 
80 102.86° - 102.86° 154.28° 
83 154.28° 102.86° - 102.86° 
86 51.42° 154.28° 102.86° -  
Figure 27.  (A) Phases of the pBLP series of plasmid, relative to the start of the 
luciferase gene.  Rotational degrees based on average of 10.5 bp/turn of the double helix.  
(B) Table of degrees of difference between the various phases of the pBLP series. 
 
 
 The pBend plasmid, named due to the incorporation of the tethered rget 
sequence, served as a precursor to the rest of the pBLP series plasmids (Fig. 26).  We 
inserted the TFO target fragment into the pBR322 plasmid at the Nhe I and BamH I 
restriction sites (Fig. 46).  The successful creation of pBend was verified through 
restriction analysis at the unique Xho I restriction site, introduced into the pl with 
the TFO target fragment. 
 The pBLP plasmid series was created through the systematic insertion of various 
DNA fragments into the pBend plasmid.  The first pBLP plasmid that we created was 
pBLP77, through the intermediate pBP77 plasmid.  The pBP77 plasmid was built by the 
insertion of the promoter fragment into pBend at the Bgl II and Sal I restriction sites (Fig. 
26).  The overhang at the 5’-end of the promoter fragment was capable of ligation to both 
-TFO ta
asmid 
48 
digested BamH I and Bgl II sites.  In placing the promoter fragment at the Bgl II position 
of pBend, the center of the tethered-TFO target sequence was located 77 base pairs 
upstream from the Nco I restriction site, where the start site of a luciferase gene would 
eventually be located.  The promoter fragment not only positioned the luciferase insertion 
site relative to the center of the tethered-TFO bend, but also incorporated the malT 
promoter upstream of the Nco I insertion site for the luciferase gene.  The unique Nco I 
 Xba I restriction sites of pBP77, introduced with the promoter fragment, served as a 
restriction analysis sites Bgl II was also used in 
verification of the successful creation of pBP77, where the lack of digestion indicated a 
loss of the Bgl II restriction si  n th on of the promoter 
gh the 
sertion of the luciferase gene into pBP77 (Fig. 26).  The 1656-bp luciferase gene was 
excised from the pGL3 plasmid at the Nco I and Xba I restriction sites and subsequently 
inserted into the pBP77 plasmid at these same sites.  The Nco I site of the pBP77 
plasmid, the location of the transcriptional start site of the luciferase gene, was positioned 
77 base pairs from the center of the tethered-TFO target sequence, where the bend in the 
DNA would occur.  The creation of pBLP77 was verified by restrictive digestion with 
Xho I and comparison of plasmid length to a similarly digested pBP77 plasmid. 
 The pBLP83 plasmid, like the pBLP77 plasmid, was built in two steps: insertion 
of the promoter fragment into pBend to create the intermediary pBP83 plasmid followed 
by the insertion of the luciferase gene into pBP83 to create pBLP83.  The pBP83 plasmid 
was constructed by inserting the promoter fragment into the pBend plasmid, as was done 
and
for verification of the pBP77 plasmid.  
te, which in turn i dic d ate e inserti
fragment. 
 The pBLP77 plasmid, the first complete pBLP plasmid, was created throu
in
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with pBP77 (Fig. 26).  Unlike pBP77, the promoter fragment was inserted into the Sal I 
and BamH I restriction sites, as opposed to the Bgl II site.  Contrasting promoter fragment 
insertion at the Bgl II site, insertion at the BamH I site did not destroy the restriction site 
sequence.  The promoter fragment included the malT promoter as well as positioned the 
Nco I site, for luciferase gene incorporation, 83 base pairs from the center of the tethered-
TFO target sequence.  We verified pBP83 through restriction analysis with Nco I and Xba 
I enzymes.  The integrity of the BamH I restriction site was also tested to verify proper 
fragment insertion. 
 The pBLP83 plasmid was obtained through the addition of the luciferase gene 
from the pGL3 plasmid into the pBP83 plasmid at the Nco I and Xba I restriction sites 
(Fig. 26).  The luciferase gene was positioned downstream of the malT promoter with its 
anscr
P77 and 
tr iptional start site located 83 base pairs from the center of the tethered-TFO target 
site, 6 base pairs further or about a half turn around the DNA double helix different than 
in the pBLP77 plasmid.  The luciferase gene in pBLP83 was phased opposite that of the 
gene in the pBLP77 plasmid.  Successful incorporation of the luciferase gene was 
confirmed through Xho I digestion and length comparison of the pBLP83 and pBP83 
plasmids via gel electrophoresis. 
 The center of the tethered-TFO induced DNA bend was phased in two opposite 
orientations, relative to the transcriptional start of the luciferase gene, in pBL
pBLP83 (Fig. 27).  Phasing the gene in the intermediary positions was accomplished 
through modification of the pBLP83 plasmid.  The pBLP80 plasmid was created through 
the insertion of the Phase 80 fragment, with a malT promoter, into the pBLP83 plasmid at 
the Xho I and Nco I restriction sites (Fig. 26).  The Phase 80 fragment altered the distance 
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between the transcriptional start site of the luciferase gene and the center of the tethered-
TFO target site, lessening the distance by 3 base pairs.  The center of the tethered-TFO 
induced bend was positioned 80 base pairs from the start of the luciferase gene in a phase 
between those of the pBLP77 and pBLP83 plasmids (Fig. 27).  The pBLP80 plasmid was 
verified by restriction analysis with Kpn I and BamH I, where Kpn I cut the pBLP80 
plasmid and BamH I did not.  The Kpn I restriction site was introduced to pBLP80 with 
the Phase 80 fragment, while the BamH I restriction site was lost when the Phase 80 
fragment was incorporated. 
III.A.3. Construction of Tethered-TFOs 
We used the tethered-TFOs of Akiyama and Hogan as bending moieties for our 
experiments.108-109   We chose to use the tethered-TFO that had previously been shown to 
achieve the maximum bend angle as our positive control and we have dubbed this the 
short TFO or STFO (Fig. 28).  The molecular tether used in this ligand was composed of 
three propylene glycol phosphodiester units and contained 18 rotatable bonds between its 
two triple helix-forming regions. 
 The pBLP86 plasmid was constructed in the same manner as pBLP80.  The Phase 
86 fragment, with a malT promoter, was inserted intp the pBLP83 plasmid at the Xho I 
and Nco I sites (Fig. 26 and 46).  The Phase 86 fragment changed the position of the 
transcriptional start site of luciferase to 86 base pairs from the center of the tethered-TFO 
target site.  This repositioning phased the center of the tethered-TFO bend opposite that 
of the pBLP80 plasmid and intermediary to the pBLP77 and pBLP83 plasmids (Fig. 27).  
The pBLP86 plasmid was verified with Kpn I and BamH I restriction analysis in the same 
manner as pBLP80. 
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Short TFO (STFO) 
5’-GGTGGGGTGGGTGGG-PgPgPg-GGGTGGGTGGGGTGG-3’ 
Broken Short TFO (bSTFO) 
5’-GGTGGGGTGGGTGGG-3’ 
 
 
 
Long TFO (LTFO) 
 
 
 
5’-PgPgPg-GGGTGGGTGGGGTGG-3’ 
Propylene glycol phosphodiester unit (Pg) 
 
the STFO and the bSTFO contained 18 rotatable bonds, while the 
O each contained 44 rotatable bonds. 
 
 In addition to the DNA-bending positive control, STFO, we needed a negative 
control.  W
span a helical turn of DNA and allow the 
 
5’-GGTGGGGTGGGTGGG-TgTgTgTg-GGGTGGGTGGGGTGG-3’ 
 
Broken Short TFO (bSTFO) 
 
5’-GGTGGGGTGGGTGGG-3’ 
5’-TgTgTgTg-GGGTGGGTGGGGTGG-3’ 
 
Triethylene glycol phosphodiester unit (Pg) 
 
 
 
Figure 28.  Sequences and molecular tether composition phosphodiester units.  The 
molecular tethers of 
molecular tethers of LTFO and bLTF
e selected the longest tethered-TFO that Akiyama and Hogan investigated as 
our negative control.108-109  This long tethered-TFO, LTFO, possessed a molecular tether 
composed of four triethylene glycol phosphodiester units with 44 rotatable bonds 
between the triplex-forming oligonucleotide arms (Fig. 28).  LTFO displayed no DNA 
bending properties due to the length and rotational freedom of its molecular tether.  The 
triethylene tether of LTFO was long enough to 
O P O
O
R'R
O
O P O
O
O
O
R O
R'
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formation of two triplexes without altering the conformation of the DNA.  We used 
LTFO as y simple 
 alterations in gene expression related to DNA bending by 
STFO. 
 We created an additional set of negative controls in the form of broken versions of 
the two tethered-TFOs, bSTFO and bLTFO (Fig. 28).  These consisted of two single-
stranded DNA oligonucleotides.  These broken oligonucleotides were created to 
r not bend pendent upon tethering of two TFOs and 
whether 
III.A.4. DNA Bending
ered-TFO-induced DNA bends on gene 
expression, we first exam our selected tethered-TFOs to bend or not.  
We used gel mobility analysis ethod DNA fragments of 
ates inversely 
128
a negative control to separate any gene expression effects caused b
tethered-TFO binding from any
determine whether o ing was de
gene expression was altered simply by the formation of DNA triplexes. 
 
 by Tethered-TFOs   
Prior to exploring the effects of teth
ined the ability of 
 to accomplish this.  In this m
identical length migrate through a gel to the same extent as long as the fragments have 
the same shape.  Different shapes (circles, linear and bent) migrate at r
proportional to the end-to-end distance of a DNA fragment; the shorter this distance the 
slower the fragment will migrate through a gel matrix.   Thus, DNA containing a bend 
will migrate slower than linear DNA due to a shorter end-to-end distance. 
 We were unable to use the pBLP plasmids created above for gel mobility analysis 
because the plasmid was greater than the persistence length of DNA.  Thus, we PCR 
amplified a region of the pBend plasmid to generate two target DNA bending fragments 
each containing the tethered-TFO binding site at a different location relative to the ends 
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of the fragment.  Two sets of primers and subsequent PCR were used to produce two 
129-base pair DNA target fragments (Fig. 29). 
A 
 
    C1:5’-CTAGCTAGCTAGTAGGAGGG-3’ 
    C2:5’-CGCGGATCCAGATCTGCTCG-3’ 
sed to create the centered TFO target DNA 
fragement, C1 and C2, and to create the end
PCR am
E1:5’-CGTGCTGCTAGCTAGT-3’ 
E2:5’-TGTAGGAGCTATAGGC-3’ 
 
B 
 
Figure 29.  (A) Sequences of PCR primers u
-located TFO target fragment, E1 and E2. (B) 
plification of 149 bp centered and end-located TFO target fragments. 
 
The C1 and C2 primers were used to amplify the TFO target DNA fragment with 
a centrally located tethered-TFO target site.  The presence of the bend directly in the 
center of the fragment would create the shortest possible end-to-end distance and thus 
correspond to the slowest possible mobility through a polyacrylamide gel.  The E1 and 
E2 fragments were used to create a DNA target with a tethered-TFO target sequence 
located at one end of the fragment.  A bend induced at this location would only affect the  
end-to-end distance to a small degree and, likewise, slow fragment gel migration only 
marginally. 
 The two target DNA fragments, centered and end-located, were complexed with 
various tethered-TFOs and analyzed by non-dentauring PAGE.  Analyzing both the 
pBend 
center 
center 
end 
end 
Centered 
TFO Target 
centering
primers 
end
primers 
End-Located 
TFO Target 
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centered and end-located fragments allowed us to determine whether shifts in the gel 
mobility of a complexed fragment was due to either DNA bending or another 
nomena, such as an increase in the molecular weight.  We expected to see the 
 the centere , slowed to a greater 
extent than any other fragme
We compared the migration of the uncomplexed tethered-TFOs, the uncomplexed 
DNA fragments and the TFO:DNA complexes in a gel mobility assay (Fig. 30).  The 
tethered-TFOs were too small to be seen in our polyacrylamide gels and migrated off the 
bottom of the gel. 
 The uncomplexed, centered TFO-target DNA fragment had mobility consistent 
with its expected size.  When coupled to STFO, the centered TFO-target DNA fragment 
In contrast, 
comple
 LTFO and the broken tethered-TFOs, the end-located target DNA fragment 
igrate
phe
mobility of d TFO target fragment complexed to STFO
nt complex. 
 
displayed the greatest loss of mobility of any DNA fragment:tethered-TFO complex, 
unning similar to the 225-bp band of the DNA ladder (Fig. 30, lane 5).  r
xes of the centered TFO-target DNA fragment and LTFO or either of the broken 
tethered-TFOs, bSTFO or bLTFO, resulted in only a minor change in mobility when 
compared to the uncomplexed DNA fragment. 
The uncomplexed end-located TFO target DNA fragment migrated similarly to 
the 125-bp band of the DNA ladder, close to its 129 bp length.  The end-located TFO 
target fragment migrated slowest when complexed to STFO with a migration similar to 
175-bp fragment, not as slow as the centered TFO target:STFO complex.  When 
complexed to
m d as a 150-bp fragment, as did the complexes of these three tethered-TFOs and 
the end-located TFO target fragment. 
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A 
 
B 
 
Figure 30.  The gel mobility assay gel picture. In the lane assignments C represents the 
fragment. (A) Lane 1, 25-bp DNA ladder molecular marker; Lane 2, STFO alone; Lane 3, 
Lane 8, E + STFO, Lane 9, E + LTFO. (B) Lane 1, C alone; Lane 2, C + STFO; Lane 3, 
STFO; Lane 8, E + bSTFO; Lane 9, E + LTFO; Lane 10, E + bLTFO. 
me manner as observed by Akiyama and 
Hogan,
gments with STFO resulted in significantly slower 
migration rates compared to their respective, unencumbered states.  However, there is a 
centered TFO target DNA fragment and E represents the end-located TFO target DNA 
LTFO alone; Lane 4, C alone; Lane 5, C + STFO; Lane 6, C + LTFO; Lane 7, E alone; 
C + bSTFO; Lane 4, C + LTFO; Lane 5, C + bLTFO; Lane 6, E alone; Lane 7, E + 
 
The gel mobility studies showed that STFO had a large effect on the migration of 
the DNA target fragments, particularly the centered target (Fig. 30).  LTFO, with a longer 
molecular tether than STFO behaved in the sa
 thus validating its use as a negative control (Fig. 30).108-109  As expected, the 
broken variants of our tethered-TFOs, bSTFO and bLTFO, were unable to bend DNA 
also confirming them as acceptable control ligands (Fig. 30).  
 Are the observed changes due to changes in the shape of the TFO:DNA 
complexes or due to the increased molecular weight of the complex?  Comparison of the 
TFO complexes with the centered and end TFO target DNA provide an answer.  
Coupling the two TFO-target DNA fra
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significant difference between the STFO:C complex and the STFO:E complex.  Since the 
molecular weight for both complexes is the same, the difference in migration is best 
explained by a difference in the conformation of the two complexes.    
 The angle of the STFO-induced DNA bend in the TFO-target DNA fragments 
was calculated using equation 1 in which θ is the bend angle, μm is the relative mobility 
 DNA fragment when the bend is at its center and μe is the relative mobility of a DNA 
fragment when the bend is at the end of the fragment.109
 
  quation 1 
 
STFO 2.18 2.79 77.23 
of a
E
 
We calculated the induced bend angles for both the STFO and LTFO tethered-TFOs from 
the gels pictured in figure 30A (Table II). 
Table II: Bending Angle Calculations for Tethered-TFO Induced Bendsa
Sample μm μe θ 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
μ
μ=θ marccos2
e
LTFO 3.39 3.39 0.00  
a The r
calculated with equation 1. 
 targe  and that reported by 
elative mobilities, μm and μe, were measured in cm. The bend angles, θ, were 
  
 STFO was able to induce a DNA bend of 77.23°, while LTFO was unable to 
induce any DNA bend.  These results were similar to those reported by Akiyama and 
Hogan; the STFO was able to induce a bend while the LTFO was not.108,110  There are, 
however, differences in the degree that STFO bent our DNA t
Akiyama and Hogan.  We calculated a bend angle of 77°, while Akiyama and Hogan 
determined that STFO induced a bend of about 53°.108,110  There are several possible 
reasons for this difference in bend angle. First, our target fragments differed from those 
used by Akiyama and Hogan.   Our 129-bp DNA targets were amplified from our pBend 
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plasmids using PCR, while Akiyama and Hogan used restriction enzymes to remove their 
171 bp targets from their own plasmids.108-109  Our target fragment was below the 
persistence length of DNA, while Akiyama and Hogan’s fragment was equal to or above 
flexible spacer of those tried by 
Akiyama and Hogan.110  Akiyama and Hogan used a different, less flexible sequence for
eir calculation of tethered
III.A.5. Regulation of Gene Expression by Tethered-TFO-Induced DNA Bending 
After verifying that our tethered-TFOs could induce a bend in our DNA target, we 
next determined whether these artificially induced DNA bends could regulate expression 
of a reporter gene.  con d t expe
tem.  This allowed us to avoid the problems of transporting 
our TFOs into cells and also avoid the problem of verifying the formation of a triplex in 
vivo.  
We coupled the various tethered-TFOs with the four pBLP plasmids, and then 
subjected the complexes to in vitro transcription and translation.  We quantified the 
luciferase produced by these complexes to determine the effect the tethered-TFOs, and 
their conformational alterations, on gene expression. 
The tethered-TFOs were coupled to linearized pBLP plasmids in a manner 
analogous to the method used in the gel shift analysis.  The pBLP plasmids (pBLP77, 
pBLP80, pBLP83 and pBLP86) were linearized by digestion with the Nde I restriction 
the persistence length. 
Second, the composition of the spacer region of our respective DNA target 
fragments is different from that previously used.  We used a spacer region that contained 
only GC base pairs which is reported to be the most 
 
th -TFO-induced bend angle.   
We ducte  his riment using an in vitro 
transcription/translation sys
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enzyme to remove the conformational obstruction presented by supercoiling and thus 
ease the formation of triplexes between the plasmids and the tethered-TFOs (Fig. 31).  
The linearized plasmids and tethered-TFOs were combined in a one-to-one molar ratio 
and allowed to complex overnight at 37°C.  Control plasmids were subjected to the 
couplin
Figure 31. Nde I linearization of the pBLP plasmid series. The “ ” on the circular and 
  
 The luciferase gene of the linearized pBLP plasmid:tethered-TFO complexes was 
expressed using the EcoPro T7 in vitro transcription/translation system system from 
Novagen.   This system utilized T7 RNA polymerase that was compatible with the  
promoters present in our pBLP plasmid series.  After incubation of our plasmid/tethered-
TFO complexes with the EcoPro system for one hour at 37°C, β-galactosidase was added 
to each reaction as an internal control.  Each reaction was then heat denatured and 
luciferase expression was analyzed by SDS-Page followed by Western analysis using 
both anti-luciferase HRP-conjugated and anti-β-galactodidase HRP-labeled antibodies.  
The Western blot was examined by chemiluminence using an ECL Western blotting kit 
and photographed using the Kodak Digital Science Image Station.  
g conditions in the absence of tethered-TFOs. 
 
~
linear plasmids represents the variable region that contains the malT promoter. 
malT
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 The amount of luciferase produced was determined by measuring the intensities 
of both the luciferase and β-galactosidase protein bands using the Kodak ID Image 
software.  From these intensities we were able to calculate the amount of luciferase 
expressed using equation 2; where Aluc is the amount of luciferase expressed (ng) in the 
sample lane, Ib-gal and Iluc are the intensities of the β-galactosidase and luciferase bands, 
spectively, and ple lane 
prior to running SDS-PAGE. 
 
 
Equation 2 
 
 We comp id in the presence 
on 3 (Fig. 
2).   
re Ab-gal is the amount of β-galactosidase (ng) added to the sam
 
ared the amount of luciferase expressed by each plasm
galb
luc
galb
luc AI
I
A −
− ⎟⎟⎠
⎞
⎜⎜⎝
⎛=
or absence of the various tethered-TFOs. We calculated the percent change for all of the 
 complexed with each of the tethered-TFOs according to equatipBLP plasmids
3
 
Equation 3 
 
 
  
 Complexes of pBLP77 and STFO resulted in a 51% reduction of luciferase 
expression, yet no statistically significant change was observed over basal levels for 
complexes of pBLP77 with the other three tethered-TFOs (Appendix A).  A statistically 
significant loss in luciferase expression was also seen in pBLP86/STFO complexes.  
When compared to the luciferase expression of the pBLP77/STFO complex, there was no 
statistical difference between the expression loss in pBLP86 and pBLP77. 
 
100100Change% −⎥⎢= A
A
luc
TFOluc ⎟⎟⎠
⎞
⎜⎜⎝
⎛
⎦
⎤
⎣
⎡ +
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A
Plasmid STFO LTFO bSTFO bLTFO 
 
pBLP77 -51.3 ± 19.3 -5.9 ± 5.5 -4.1 ± 5.3 -4.0 ± 9.2 
pBLP80 31.1 ± 13.3 -1.4 ± 5.9 -1.2 ± 7.5 -0.2 ± 3.4 
pBLP83 93.3 ± 23.5 9.8 ± 6.4 10.8 ± 6.6 2.6 ± 5.6 
pBLP86 -35.2 ± 4.6 -0.6 ± 3.1 -0.1 ± 2.7 -2.0 ± 4.1  
 
Figure 32.  Averaged percen on from uncomp
plasmids. (A) Percent change in luciferase expression for each plasmid com
tethered-TFO as compared to the same, uncomplexed plasmid; all values are percentages. 
t STFO complexes, the black bars represent LTFO 
ponding basal 
ciferase levels.  These elevated expression levels were significantly different from the 
B 
t change in luciferase expressi lexed pBLP
plexed to a 
 
(B) The green bars represen
complexes, the blue bars represent bSTFO complexes and the white bars represent 
bLTFO complexes.  These are the averaged results of six assays for pBLP77 and pBLP83 
and five assays for pBLP80 and pBLP86. 
 
 In contrast to the loss of luciferase expression seen in complexes of pBLP77 and 
pBLP86, a marked increase in luciferase expression was observed when STFO was 
complexed with either the pBLP80 or the pBLP83 plasmids.  The increased expression 
levels were elevated to 31.1% and 93.3%, respectively, above the corres
lu
-100
0
25
50
125
     pBLP77 pBLP80 pBLP83      pBLP86
%
 C
ha
ng
e
75
100
-75
-50
-25
61 
decreased luciferase expression levels witnessed in complexes of STFO and either 
pBLP77 or pBLP86.  In contrast, there was no statistical difference in luciferase 
expression for comp LP8 LP83 FO, b d bLTFO.  
eed, when all complexes of LTFO, bSTFO and bLTFO are examined, there is no 
 
xed 
on.  
e 
rase 
ed with varying distances between the center of 
the tethered-TFO target sequence and the transcriptional start of the luciferase gene.  The 
variation in this distance correlated to a change of phase in the induced bend of the DNA 
due to differences in the relationship of these two sites in terms of three-dimensional 
orientation (Fig. 27).  We expected to see an increase in luciferase expression when a 
bend was introduced in one of the pBLP plasmids with a corresponding decrease in the 
lexes of pB 0 and pB  with LT STFO an
Ind
statistically significant difference between the luciferase expression levels of any of the 
complexes. 
Our data indicates that tethered-TFO-induced DNA bends are able to affect the 
levels of luciferase expression in the manner that we predicted.  STFO, shown to induce a 
DNA bend in our gel mobility studies, demonstrated the greatest effect when comple
to the pBLP plasmids, whether increasing or decreasing the level of luciferase expressi
On the other hand, all of the negative controls, which are unable to bend the DNA, do not 
significantly affect the expression of luciferase.  The lack of a significant effect on 
luciferase expression by LTFO indicates that the bend induced by STFO, and not som
other factor, is the most likely explanation for the observed change in lucife
expression.   
 The luciferase expression experiment verified the role of DNA bending in 
artificially regulating gene expression when the results were viewed in terms of bend 
phasing.  The pBLP plasmids were design
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pBLP plasmid that was phased opposite it.  In addition, intermediary effects were 
expected for the other two plasmids of the series which are phased in between the 
plasmids.  In our experiment the pBLP83:STFO displayed nearly double the basal 
expression level of the uncoupled plasmid.  On the other hand, pBLP77, with an induced 
bend opposite the pBLP83 bend, displayed a loss of about half of the luciferase 
expression seen in the basal expression of the gene in this plasmid.  The intermediary 
onality was opposite that of the enhancing, or in-phase, orientation, resulted 
III.B. Project 2: A Sequence Selective Push Bender 
 We were able to demonstrate that the expression of a target gene could be 
influenced, both up- and down-regulated, through phased DNA bends induced upstream 
of the gene by tethered-TFOs.  Unfortunately, tethered-TFOs are poor pharmaceutical 
candidates.  Ideally, artificial gene regulation through DNA bending would be 
pBLP plasmids displayed luciferase expression levels less extreme than those seen in 
pBLP83 and pBLP77 when bent by STFO. 
 The results of our gene expression assay were consistent with those of the 
replacement studies that explored the role of DNA bending in gene transcription.102-105  
As demonstrated in the replacement studies, gene expression was enhanced when 
artificial DNA bends were introduced in one orientation, in the pBLP83 complex, in a 
direction presumably analogous to those introduced by native DNA bending 
proteins.23,93,102-105  Altering the orientation of the artificially induced DNA bend such 
that its directi
in a loss of gene expression.  This decrease or loss of gene expression due to an out-of-
phase bend was also observed in the replacement studies.23,93,102,104
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accomplished through small molecules capable of passing through membrane barriers, 
selectively binding to a specific DNA sequence and inducing a DNA bend upon binding.  
These small molecules would function as push bending agents; widening the minor 
groove of a DNA target upon binding.  In the second project of this thesis we synthesized 
three DNA push bending agents (Fig. 24), tested them for DNA binding preference and 
the ability to induce a bend in a DNA target. 
III.B.1. Synthesis of 2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-
carboxylic acid (3-dimethylamino-propyl)-amide, 1   
Scheme Ia
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60°C, 75% yield; (iii) 3-(dimethylamino)propylamine, HBTU, NMM, DMF, 51% yield. 
The construction of 1 (Scheme I) was accomplished by condensation of N-
methylpyrrole-2-carboxylic acid and ethyl-2-amino-4-phenyl-5-thiazole carboxylate 
using standard peptide bond coupling conditions (EDCI, DMAP) as described by Boger 
l.12
carboxylic acid, , in good yield.  The addition of the necessary cationic tail was again 
use the more reactive HBTU and NMM as coupling conditions for the formation of the 
aReagents: (i) EDCI, DMAP, DMF, room temperature, 62% yield; (ii) LiOH/methanol, 
 
et a 9  The resulting product, 4, was hydrolyzed with 1N LiOH to generate the free 
5
performed using standard peptide coupling conditions.  We found that is was necessary to 
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final peptide bond.130  Purification of the final product, 1, using standard silica gel 
chromatography provided the desired material in 51% yield. 
 
III.B.2. Synthesis of {5-[5-(3-Dimethylamino-propylcarbamoyl)-4-phenyl-thiazol-2-
ylcarbamoyl]-1-methyl-1H-pyrrol-3-yl}-carbamic acid tert-butyl ester, 2   
Scheme IIa
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aReagents: (i) EDCI, DMAP, DMF, room temperature, 52% yield; (ii) LiOH/methanol, 
60°C, 72% yield; (iii) 3-(dimethylamino)propylamine, HBTU, NMM, DMF, 60% yield. 
 
Condensation of 4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carboxylic 
e desired product, 6 in 52% yield (Scheme II).  Hydrolysis of the ethyl ester  with 
lithium
acid and ethyl-2-amino-4-phenyl-5-thiazole carboxylate using EDCI, DMAP generated 
th
 hydroxide generated the  acid, 7, which was reacted with 3-(dimethylamino) 
propylamine under conditions similar to those for the preparation of 1 to yield the final 
product 2 in 60% yield. 
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III.B.3. Synthesis of 2-[(4-Formylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-
phenyl-thiazole-5-carboxylic acid (3-dimethylamino-propyl)-amide, 3 
cheme IIIaS
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O N
S
O
HN
N CH3
H3C
NH
O
O
N
CH3
H
N
O N
S
O
HN
N CH3
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H
i, ii
2 3  
aReagents: (i)  CH2Cl2, benzenethiol, TFA, room temperature; (ii) Ethanol, ethyl formate, 
reflux, 73% yield. 
 
The formamide derivative of 2, compound 3, was obtained as outlined in scheme 
III. Deprotection of the Boc group with trifluoroacetic acid and benzenethiol yielded the 
free amine which was immediately reacted with ethyl formate to yield 3 in 73% overall 
I.B.4. DNA Binding of Compounds 1, 2 and 3   
on of compound concentration, we were able to determine the 
inding constants for each compound for each DNA target. 
 this assay, we investigated the ability of our compounds to bind to three 
different DNA targets; to an AT-rich sequence of DNA, a GC-rich sequence of DNA and 
yield. 
II
We used an ethidium bromide displacement assay to determine the binding 
affinities and sequence preference of compounds 1, 2 and 3.  Ethidium bromide (EtBr) 
fluoresces when bound to DNA, but possesses only weak fluorescence in the absence of 
DNA.  Thus, displacement of bound EtBr from DNA by other DNA binding agents 
would result in a decrease in the fluorescence signal.  By measuring changes in the 
fluorescence as a functi
b
In
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ScaI-linearized pUC19 plasmid.  The AT-rich and GC-rich DNA target sequences we
generated from an oligonucleotide that could adopt a hairpin structure (F
re 
ig. 33).  The Sca 
lasmid was created by digestion of pUC19 with ScaI restriction enzyme and 
was used as a representation of a random sequence of AT and GC base pairs. 
A B 
NA hairpin targets investigated in the ethidium bromide displacement 
ssay, (A) the AT target and the (B) GC target. 
 
 
 The binding constants for compounds 1, 2 and 3 utilized a method published by 
129
ethidium bromide in assay buffer, while the maximum fluorescence (100%) was set equal 
to the fluorescence of ethidium bromide bound to the various dsDNA targets prior to 
a function of the concentration of the 
individ
%. 
 
   Equation 4 
 
5’-CG
I-linearized p
 
 
 
Figure 33.  The D
a
Boger, et al.   The collected data was normalized to the background fluorescence of 
titration of the compounds. The data collected as 
ual compounds were converted into a percentage of this maximum fluorescence, 
after being normalized to the background (Fig. 34).  
 The binding constants for compounds 1, 2 and 3 were found using equation 4; 
where Kcompound is the binding affinity of the drug to the target DNA, KEB is the binding 
coefficient for ethidium bromide for the DNA targets, [EB] is the concentration of 
ethidium bromide present, and [compound]50 is the concentration of drug that reduced the 
fluorescence of the ethidium bromide/DNA complexes by 50
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Table III: Binding Constants of Compounds 1, 2 and 3 
Compound & Target a [Compound]50 (x 10-4 M) Kcompound (x 106 M-1) 
Netropsin + 5'-AATT-3' - b25.0 
Netropsin + 5'-ATAT-3' - b2.2 
Distamycin + AT-hp - c6.5 
1 + AT-hp 1.6720 0.026 
1 + GC-hp 9.8650 0.004 
2 + AT-hp 5.8335 0.008 
2 + GC-hp 5.7950 0.008 
2 + pUC19 6.7405 0.007 
3 + AT-hp 1.3965 0.032 
3 + GC-hp 9.0350 0.005 
3 + pUC19 6.0900 0.007  
a: hp represents hairpin DNA.  b: Sidorova et al., 1995.  c: Boger et al., 2000. 
 
For our data, we used KEB of 10 x 106 M-1 for all calculations with [EB] at 4.4 x 10-6 
M.129 The calculated binding constants are presented in table III along with the binding 
constants of netropsin for two different AT target sequences and for distamycin for the 
AT-rich DNA hairpin.48,129  Compounds 1 and 3 displayed binding preferences for the 
AT-rich hairpin DNA over the other DNA targets as demonstrated by their binding 
constants. Compound 2, on the other hand, showed no preference for a single DNA 
target, binding to all three at comparable levels, all of which were less than that of 
compounds 1 and 3 toward the AT-rich hairpin.  Compounds 1, 2 and 3 all displayed 
binding constants two or three orders of magnitude less than a related compound, 
netropsin, towards the DNA targets. 
 Our compounds were designed with the goal of creating sequence specific DNA 
minor groove push bending molecules.  The ethidium bromide displacement assay 
verified that compounds 1 and 3 bound to DNA with a noticeable level of sequence 
specificity.  Compounds 1 and 3 displayed a five to six-fold greater preference for AT-
ch DNA sequences over GC-rich and random DNA sequences.  The sequence 
discriminate, low level DNA binding displayed by compound 2 was most likely due to 
ri
in
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the tert-butoxycarbonylamino group at the head of the compound and the steric hindrance 
that it pr  compound fr  binding in the  
The lower binding constants, as compared to netropsin and distamycin, of compounds 1 
and 3 co ed to the inclusion of t yl ring at the 4-p  of the thiazole.  
The bulk of the ring may have dramatically effected the positioning of our compounds in 
the minor groove and the ability of the m ove binding edge pounds to 
 lexitropsins 
isplayed an inability to bind to DNA, let alone AT-rich DNA sequences, though the 
e of DNA bending.  We compared the fluorescence 
esented, preventing the om minor groove at any site. 
uld be relat he phen osition
inor gro  of the com
fully interact with the floor of the minor groove.  Other thiazole-containing
d
majority of these compounds contained a substituted thiazole ring configured such that 
the nitrogen atom was on the minor groove binding edge of the compounds.130
III.B.5. DNA Bending by Compounds 1, 2 and 3 
We determined the ability of compounds 1, 2 and 3 to alter the conformation of 
DNA upon binding using fluorescence resonance energy transfer (FRET) analysis.  FRET 
measures the distance between two fluorescent dyes, located at the 5’- and 3’-ends of a 
DNA target.  Changes in the conformation of DNA, due to bending, should result in a 
change in the FRET signal between the two dyes.  Thus, changes in the FRET signal 
upon drug binding would be indicativ
levels of two identical dsDNA sequences end-labeled with different dyes in the absence 
and presence of compounds 1, 2 and 3 (Fig. 35). 
The target FRET DNA sequence was 19-bp in length with an AT-rich central 
sequence.  This target sequence was selected due to the AT sequence preference 
demonstrated by the compounds in the ethidium bromide displacement assay.  
Fluorescein and tetramethylrhodamine were selected as our FRET dyes as these dyes 
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have been used by other research groups investigating conformational changes in 
DNA.131  The first of our DNA target sequences, the donor fragment, possessed a single, 
5’-terminal fluorescein moiety, FAM.  Our other target DNA fragment, the donor-
acceptor fragment, was labeled with a 5’-terminal FAM as a FRET donating group and a 
RET acceptor. 
t in the donor sequence spectrum due to 
fluores
3’-       CTACGGCTTTAAGGCGAAG(TAMRA)-5’ 
Figure 35.
fluorescence donating F  
A        
5’-(6-FAM)GATGCCGAAATTCCGCTTC-3’ 
3’-       CTACGGCTTTAAGGCGAAG-5’ 
 
B        
5’-(6-FAM)GATGCCGAAATTCCGCTTC       -3’ 
 
  The two fluorescently labeled DNA fragments for FRET analysis. (A) This 
fragment contains only the FAM fluorescence donor moiety, while (B) contains both the 
AM moiety but also the fluorescence accepting TAMRA moiety.
3’-terminal tetramethylrhodamine, TAMRA, as a F
Samples of each fragment were excited at 495 nm in the absence of the 
compounds and the emission spectra for each were recorded from 500 nm to 700 nm.  
The emission spectra for both the donor sequence and the donor-acceptor sequence can 
be seen in figure 36.  While the emission spectrum for the donor sequence contained a 
FAM peak at about 520 nm, the spectrum of the donor-acceptor target contained two 
peaks; one at about 520 nm corresponding to FAM and a second, smaller peak at about 
580 nm corresponding to energy transfer to TAMRA.  The FAM peak of the donor-
acceptor sequence spectrum was smaller than tha
cence resonance energy transfer.  After analysis of the two DNA sequences alone, 
excess amounts of compounds 1, 2 and 3 were added, incubated and then excited at 495 
nm.  The emission spectra from 500 nm to 700 nm were then recorded (Fig. 36). 
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 Changes in the conformation of the DNA targets were calculated based on the 
differences in the  presence of the 
ds.  The bending caused by the binding of our compounds was calculated by 
comparing the d without the 
equation E was the efficiency of energy transfer; Φ was the integrated intensity of 
Equation 5 
 
 
No compound 0.249 ± 0.015 58.9 ± 0.7 55.3 ± 2.7 0.0 
spectra of the DNA target in the absence and
compoun
conformations of the FRET DNA target fragments with an
compounds.  To calculate these conformations, the efficiency of the energy transfer from 
the donor moiety to the acceptor moiety was determined using equation 5.131   In this 
D
em
emission from 510 to 530 nm of DNA duplex with only the donor moiety; emΦ  was the 
integrated intensity of emission from 510 to 530 nm of donor-acceptor labeled DNA 
duplex. 
 
DA
⎟⎜1E ⎟
⎞⎜⎛ Φ−=
D
em
⎠⎝ Φ DAem
 The calculated efficiencies of energy transfer are shown in table IV.  The 
efficiency of energy transfer decreased when any of the compounds were bound to the 
DNA, though this loss in efficiency was greater for compounds 1 and 3 than compound 2.   
The energy transfer between the FAM donor and the TAMRA acceptor was less efficient 
when the FRET DNA target was complexed with any of our compounds.  
Table IV: FRET Derived Bending Data for Compounds 1, 2 and 3 
 
Compound Ea Rb (Å) θc (°) Δθd (°) 
1 0.156 ± 0.004 65.0 ± 0.3 24.8 ± 2.8 -30.6 
2 0.217 ± 0.008 60.7 ± 0.5 48.3 ± 2.1 -7.0 
3 0.162 ± 0.017 64.5 ± 1.3 28.5 ± 8.7 -26.8 
  
: Efficiency of energy transfer; : End-to-end distance; : Bend angle from linea
linear is 0°; 
a b c r, where 
t bound 
compound. 
 
d: Change in bend angle from FRET DNA target fragment withou
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The end-to-end distance of the FRET DNA fragments is indirectly related to the 
efficiency of energy transfer.  The more efficient the energy transfers within a DNA 
fragment, the closer together the ends of the fragment.    The relationship between the 
efficiency of energy transfer and the distance between the two fluorescent dyes is given 
by equations 6 and 7.131  In these equations, E represents the efficiency of energy 
transfer; R represented the end-to-end distance of interest; and R0 was the “critical 
distance” at which energy transfer from donor to acceptor and spontaneous decay of 
donor is of equal probability. R0 was a constant and is dependent upon the FRET pairs 
chosen.  For our system, R0 was 49 Å.   
 
Equation 6 
 
 
Equation 7 
 
 The end-to-end distances calculated by equation 7 are shown in table IV.  The 
maximum end-to-end distance for the two DNA sequences used in this FRET analysis, 
representing a completely straight strand of DNA, was 66.5 Å, based on the accepted 
average distance of 3.5 Å/DNA bp.  The calculated end-to-end distances showed an 
unexpected trend.  Upon addition of compounds 1, 2 and 3 the end-to-end distances of 
the target DNA sequences did not decrease, as expected, but rather increased approaching 
the maximum length of these DNA sequences.  The increased end-to-end distances and 
decreased efficiencies of energy transfer suggested that the FRET DNA targets were 
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becomi
Figure 37.  Relationship of end-to-end distance, R, of the FRET DNA fragments and 
ce R results in an increase in the θ angle and, 
conversely, increasing distance R results in a decrease in angle θ.  The maximum distance 
r R was the linear length of the D nt, 66.5 Å, with a θ angle of 0°. 
 
 The end-to-end distance of the FRET DNA in the presence and absence of our 
compounds allowed us to calculate the bend angles that were present in the various 
complexes (Fig. 37).  As the end-to-end distance of the DNA fragments decreased, the 
fragment becomes more bent in relation to e assumed that our compounds 
ng more linear and, therefore, less bent.  This appears to be opposite of our 
original goal. 
 
angle from linear, θ.  Decreasing distan
5’- 6-FAM 
TAMRA -3’ 
R
θ
fo NA fragme
 linear DNA.  W
were exerting their effects from the direct center of the FRET DNA target fragments, the 
center of the 5’-AAATT-3’ binding site, and we set the linear length of the FRET DNA 
to be 66.5 Å(19-bp at 3.5 Å/bp).  From these assumptions, we used equation 8 to 
calculate the bend angle relative to linear DNA.  In equation 8, θ is the bend angle as seen 
in figure 37, R is the end-to-end distance of the DNA and R0 is the maximum linear 
length of the DNA fragment (66.5 Å). 
Equation 8 
 
⎟⎟
⎞
⎜⎜
⎛=θ −1
R
Rcos2
⎠⎝ 0
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The unliganded DNA displayed a bend greater than any of the complexes with 
our compounds.  The bend in the DNA target fragment was calculated to be 55° from 
linear.  This bend was sequence derived and, therefore, intrinsic in nature.  The AT-rich 
target sequence located in the center of the DNA target was the most likely source of the 
intrinsic bend due to both the increased flexibility of AT-rich sequences and the steric 
interactions between the adjacent adenines causing a bend in the DNA as in an A-tract, 
widening the major groove and bending the DNA toward the minor groove.72-73,78-80
Our compounds demonstrated a lower efficiency of energy transfer, a greater end-
versus the 
absence of our compounds (table IV).  As seen in table IV, compounds 1 and 3 appeared 
to have straightened the bend of the DNA target sequence by about 30°.  Compound 2, 
which possess poor DNA binding ability, altered the bend of DNA by only about 7°. 
Our compounds were designed as minor groove-binding push bending agents.  
However, complexes of DNA and our compounds resulted in more linear DNA 
fragments, as opposed to DNA fragments with DNA bending as expected.  In order for 
the statically bent sequence of DNA to obtain a more linear conformation a force 
opposing the adenine-derived bend has to be applied to the DNA.  It is known that the 
adenine-derived DNA bend is caused by a compression of the minor groove of DNA.  
Our compounds bind to the minor groove and widen it through interactions between the 
minor groove walls and the phenyl ring pres pounds.  Pushing the minor 
groove open in the intrinsically , would result in a bend 
to-end distance and a corresponding decrease in bend angle.  The change in bend angle, 
Δθ, was calculated as the difference between the bend angles in the presence 
ent in our com
 bent FRET DNA target, however
76 
in oppo
IV. DISSCUSSION 
 the 
gene (7
luciferase expression as a function of the distance, in base pairs, between the center of the 
tethered-TFO-induced DNA bend and the start of the luciferase gene, it is apparent that 
sition to the naturally occurring bend at the target site and would ultimately result 
in forcing the DNA into a more linear conformation. 
 
 
IV.A. Project 1: Tethered-TFOs and Gene Regulation 
The objective of this project was to examine whether artificially-induced DNA 
bends could affect gene expression.  Our studies showed that STFO was able to bend 
DNA and regulate gene expression to a far greater degree than the other tethered-TFOs 
tested (Fig. 32).  The effect of this regulation was dependent upon the distance between 
the bend and the start of the luciferase gene.  When STFO was coupled to pBLP77, the 
plasmid with the shortest distance between the center of induced bend and the start of
7-bp), the greatest loss in gene expression was observed.  However, when the 
center of the bend was moved 6-bp farther (pBLP83), the induced bend was moved to the 
opposite face of the DNA.  At this position, the amount of luciferase expressed was 
nearly doubled.  This dichotomy was expected, confirming our hypothesis that non-
protein driven, DNA conformational changes alone could influence the expression of a 
gene. 
The data from the gene expression assay indicated that changing the distance 
between the center of the tethered-TFO-induced DNA bend and the start of the luciferase 
gene would result in a change in level of gene expression.  Plotting the percent change in 
77 
there is a cyclic function to the data (Fig. 38).  It is interesting to note that the same cyclic 
function is observed for the relationship between distance and bend angle for intrinsically 
ent DNA and is reminiscent of plotted gel mobility data for DNA fragments with 
ariably positioned DNA bends.109  This relationship lends credence to the fact that DNA 
bending is directly related to gene expression. 
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Figure 38.  Graph depicting the experimental percent change in luciferase expression 
bend and the start of the luciferase gene (black circles) and the curve from equation 10 
(black line). 
The data outlined in figure 38 is best fit with a sine function.  The general formula 
for a si
Equation 9 
ne curve is shown in equation 9.  The result y is a function of x where A is the 
amplitude of the sine curve, w is the period of repetition (in radians), φ is the phase shift 
of the curve and B is the vertical shift of the sine curve.   
 
( ) BwxsinAy +φ−=
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From equation 9 and the gene expression assay data (Fig. 32), equation 10 was 
derived to describe the change in luciferase expression as a function of the distance 
between the induced DNA bend and the luciferase gene.  
 
Equation 10 
 
In equation 10, E is the percent change in luciferase expression and b is the distance in 
base pairs from the center of the tethered-TFO target sequence to the start of the 
luciferase gene.  The amplitude of the equation, A, was estimated to be about 85; the 
period of the equation, w, was based on 10.5-bp/turn, and was equal to 2π/10.5 or about 
0.5984; the vertical shift, B, was calculated to be 15; and the phase shift value, φ, was 
calculated to be 1.5708.  The phase shift value, φ, was set such that the trough of the 
curve fell at 77-bp, the low point of the experimental data.  Equation 10 best fit the 
experimental data and fell within the experimental error for each data point.  
and, the greatest increase in luciferase expression, +100%, would occur at 82.25-bp.  
Since n
( )[ ] 155708.177b5984.0sin85E −−= +
 Based on equation 10, the greatest loss in luciferase expression, -70%, would 
occur when the center of the induced bend was positioned 77 base pairs upstream of the 
start of the luciferase gene; and every 10.5-bp increment from this point.   On the other 
h
o base pair can occur at this point, it is impossible to achieve a 100% increase in 
gene expression.  The maximum achievable increase in luciferase expression would occur 
at a distance of 82 base pairs between the center of the induced bend and the luciferase 
gene with a +99.1% increase in gene expression.   
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We have demonstrated that artificially-induced, phased DNA bends were able to 
alter gene expression levels.  How these induced DNA bends were influencing gene 
expression remains to be answered.  There are two theories that can explain how DNA 
ending can change gene expression.  These theories are DNA wrapping and RNA 
polymerase interactions with art of the
mechanisms have been described in the literature. 
between the 
 by facilitating DNA wrapping around 
the RNA polymerase (Fig. 39B).  Facilitating DNA wrapping would decrease the energy 
b
proteins or DNA upstream of the st  gene.  Both 
In both prokaryotic and eukaryotic systems, RNA polymerase has been shown to 
wrap DNA around itself after it binds to the promoter.  Previous studies have shown that 
the DNA wraps about 300° around the polymerase.  To accomplish this, about 90 
consecutive base pairs are needed to come into contact with the RNA polymerase.  
Footprinting studies have shown that the base pairs range from the -70 to the +20 
position.83,94-96  
Induced DNA bends could have affected DNA wrapping either facilitating or 
hindering the wrapping around RNA polymerase.  The major difference 
various TFO:DNA complexes was whether a DNA bend had formed and what was the 
orientation of that bend.  Both of these factors could affect DNA wrapping.  The out-of-
phase, STFO-induced bends seen in complexes with pBLP77 and pBLP86 plasmids may 
have altered the conformation of DNA such that it was unable to wrap around RNA 
polymerase (Fig. 39A).  The end result of this would be a weaker RNA polymerase:DNA 
complex, which would lead to a decrease in the efficiency of transcription.  Conversely, 
the increased levels of luciferase expression witnessed in the pBLP80:STFO and 
pBLP83:STFO complexes could also be explained
80 
required, which would enhance binding of RNA polymerase and thus increase 
transcription.  The other TFOs that have no effect on DNA conformation, LTFO, bSTFO 
and bLTFO, should have no effect on either RNA polymerase binding or on DNA 
wrapping (Fig. 39C). 
A 
 
 
B 
 
C 
 
phase bends pre
Figure 39.  Role of tethered-TFO induced DNA bending in DNA wrapping.  (A) Out-of-
vent DNA wrapping around RNA polymerase resulting in the down 
regulation of luciferase expression.  (B) In-phase bends facilitate DNA wrapping that 
enhanc
wrapping to occur normally with baseline levels of luciferase expression.  
es luciferase expression.  (C) Tethered-TFOs that did not bend DNA allow DNA 
 
 Another mechanism by which tethered-TFO induced DNA bends could have 
affected the luciferase expression involved the inhibition or activation of protein-protein 
or protein-DNA interactions to RNA polymerase (Fig. 40).  Again, the overall effect on 
gene expression would be dependent on the orientation of the bend relative to the start of 
the gene.  An in-phase bend would facilitate interactions with upstream proteins or DNA, 
which in turn would increase gene expression.  Conversely, an out-of-phase bend would 
hinder interactions and result in the down regulation of luciferase expression.  Tethered-
TFOs that did not affect the conformation of DNA would have no affect on the 
occurrence of these interactions and, consequently, luciferase expression would occur at 
81 
the baseline level. Although we cannot definitively rule out this mechanism, we believe 
that it is high unlikely to occur in our system for two reasons.  First, our vectors were not 
designed with binding sites for transcription factors. Second, the EcoPro T7 
transcription/translation system lacks these transcription factors due to the kit being 
igned to function with only a T7 or E. coli promoter. 
A 
B 
 
C 
 
polymerase, RNA Pol, and upstream proteins, UP.  (A) Linear DNA without tethered-
phase bends facilitate contact between RNA Pol and UP, up activating transcription.  (C) 
 
 Regardless of how tethered-TFO induced DNA bends were affecting gene 
expression, these results demonstrate that the induction of a DNA conformational change 
upstream of a gene can alter gene expression.  This method of gene control presents a 
single mechanism by which a gene can be either activated or inhibited, dependent on the 
location and subsequent phase of an induce bend.  This mechanism offers the potential 
for the development of a new class of gene expression controlling pharmaceutical agents. 
Upstream 
Protein 
Binding Site 
RNA Pol 
Binding Site 
des
UP RNA Pol 
Transcription 
Activated 
Transcription 
Activated 
Transcription 
Inhibited 
Figure 40. Role of phased DNA bends in facilitating interactions between RNA 
TFOs or with non-bending tethered-TFOs display normal levels of transcription.  (B) In-
Out-of-phase bends inhibit transcription by preventing interaction between the proteins. 
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 Our study demonstrated the ability to alter gene expression with the induction of 
phased DNA bends upstream of RNA polymerase bind.  The future development of 
pharmaceutical agents for the treatment of gene expression related diseases will require 
further exploration of this mechanism in eukaryotic systems.  Nucleosome packaging 
plays an important role in eukaryotic transcription and will have to be dealt with for gene 
ression to be altered by artificially induced DNA bends.132-133
 
IV.B. Project 2: A Sequence Selective Push Bender 
The tethered-TFO bending project verified that a non-protein moiety could induce 
nd in DNA and affect the expression of th ne, validating the artificial induction of 
phased DNA bends as a mechanism to alter gene expression.  It is unlikely, however, that 
tethered-TFOs themselves would be useful medicinal agents due to their size and 
complexity.  The ideal agent would be a small molecule that could bind to a specific 
sequence of DNA and induce a bend to alter gene expression in the manner demonstrated
Currently, there are a number of compounds that are capable of binding to DNA 
exp
a be e ge
 
by the tethered-TFOs.  Thus, the objective of the second project was to explore the design 
of small molecule, sequence specific DNA bending agents. 
 
and some of these display sequence selectivity.   Among the most selective DNA binders 
are the polyamide and lexitropsin classes of compounds.  These compounds interacted 
with hydrogen bond donors and acceptors presented by nucleotides in the minor groove 
of the DNA duplex.  Polyamides have served as useful molecules to delivery other 
functions to DNA and thus were logical choices for the construction of DNA bending 
agents.  
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 In contrast to the minor groove binding agents, there are relatively few molecules 
that are capable of changing the conformation of DNA and most of them display poor 
sequence selectivity.  However, we used some of the design principles found in existing 
DNA bending agents like ET-743 to construct our agents. ET-743 induces a 
conformational change in DNA through steric interactions between minor groove walls 
of the binding site and the perpendicularly displayed bulky aromatic ring system of the 
olecule.  The bulk of the ring system widened the minor groove causing a 
corresponding compression of the major groove on the opposite face of the DNA, 
resulting in a DNA bend. 
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Figure 41. Netropsin and the three analogues; 1, 2 and 3. 
a manner analogous to ET-743.  We chose to use a phenyl ring since the phenyl 
 
We designed a series of compounds that incorporated the minor groove binding 
specificity of polyamides with the DNA bending mechanism of compounds like ET-743.  
Compounds 1, 2 and 3 included structural features of the minor groove binding agent 
netropsin and like netropsin, our molecules bound to AT-rich DNA sequences (Fig. 41). 
Compounds 1-3 were also designed to present bulky group into the minor groove of their 
target in 
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group would adopt a perpendicular orientation relative to the planar shape of the rest of 
the molecule which would allow it to sterically interact with walls of the minor groove.  
The compounds were synthesized in a straightforward manner analogous to other known 
minor groove binding agents. 
 An ethidium bromide displacement assay was used to determine the binding 
constants and sequence preferences of our compounds.  Compounds 1 and 3 displayed 
the expected preference for AT-rich DNA sequences with 1 displaying about a 7-fold 
preference for the AT-rich target while 3 showed a 6-fold preference.  Compound 2 
demonstrated similar binding constants for all three DNA targets indicating that it was 
most likely a non-specific binding agent.  The presence of a bulky group in the N-
terminal position in compound 2 must have been great enough to prevent the compound 
from correctly positioning itself in the minor groove of an AT base pair.   
The observed binding constants for all three compounds were 300 to 2000-fold 
less than the reported binding constant of netropsin for AT-rich DNA.48  Our compounds 
differ from the model molecule, netropsin, by the substitution of 4-phenyl-thiazole for an 
N-methylpyrrole and utilization of different N- and C-terminal tail groups.  The 
r netropsin and our compounds 
could be attributed to these replacements.  
The thiazole of our compounds incorporated a sulfur atom in place of a vinyl at 
the 1 position of the ring.  The sulfur atom was larger than the original carbon atom and 
may have prevented optimal alignment of our compounds in the minor groove of the 
target DNA.  The incorporation of thiazoles into the minor groove binding region of a 
polyamide compound had previously been used to selectively target the adenine over the 
discrepancy in binding affinities between that reported fo
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thymine of an AT base pair, due to alterations in the alignment of the N-terminal amide –
NH in the minor groove.55  This sequence preference may also have affected the binding 
of our compounds to an AT-rich DNA target by our compounds not aligning with the 
minor groove in the most advantageous manner. 
onated tail and 
the N3
ine O2 groups in the minor groove, a feature 
missing
In addition, the phenyl ring attached to the minor groove binding region of our 
compounds protruded perpendicularly from the minor groove, as seen in molecular 
modeling (Fig. 25). The lower binding affinities of compounds 1-3 could have been the 
result of steric interactions between the phenyl ring and the minor groove, shifting the 
position of the compounds in the minor groove resulting in less favorable alignment with 
the hydrogen bond acceptors in the minor groove. 
Netropsin possessed a guanidine tail at its N-terminus.  This tail interacted with 
the minor groove of DNA by forming hydrogen bonds between the prot
 position of adenines.134  The replacement of this group with a proton or a bulky 
chain would prevent the formation of this hydrogen bond, resulting in the poorer binding 
affinities observed for these compounds toward the minor groove of AT-rich DNA 
sequences.  The formamide group at the N-terminus of compound 3 also lacks this 
additional hydrogen bond, but maintains an amide –NH at this terminus to form a 
hydrogen bond with adenine N3 and thym
 from compound 1. 
 Like the N-terminal guanidine, the C-terminal amidine of netropsin also played a 
role in binding to the minor groove of AT-rich DNA sequences, specifically to the N3 
position of adenines.134  Dimethylaminopropylamide, like the C-terminal amidine tail of 
netropsin, is protonated under physiological conditions allowing it to interact with the 
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minor grooves of AT base pairs.126  The replacement of this amidine tail with a 
dimethylaminopropylamide tail has been shown to result in decreased binding 
affinities.126-127  This decrease, however, was not severe enough to explain the 300 to 
2000-fold difference in binding affinities between our compounds and netropsin.  The 
dimeth
h steric interactions.  Using FRET, we 
had exp
is validated based upon the efficiencies of energy transfer of 
ylaminopropyl-amide tail has been utilized in a number of polyamide and 
lexitropsin derivatives due to the increased hydrophobicity which increases membrane 
transport and forms favorable hydrophobic controls with the methylenes of the sugar 
group in the minor groove.125
 The inclusion of a bulky group into compounds 1 and 3 was done to induce a 
bend in DNA by widening the minor groove throug
ected to see an increase in the efficiency of energy transfer in the presence of our 
compounds, indicating the induction of a bend.  This would correlate to DNA bending. 
However, we observed the opposite effect.  All three compounds decreased the efficiency 
of energy transfer between the fluorescent donor and acceptor.  These lower efficiencies 
corresponded to an increase in the end-to-end distance with the drug:DNA complex being 
1 to 5 Ǻ longer than the uncomplexed DNA. 
 The longer end-to-end distance indicates that the binding of compounds made the 
DNA targets more linear.  Consequently, this suggests that the unliganded DNA target 
was bent.  This conclusion 
the uncoupled target DNA fragment.  These measurements reveal that the end-to-end 
distance of our target DNA fragments is about 58.9 Å, shorter than a completely linear 
DNA strand with the same number of base pairs (66.5 Å).  We believe that the AT-rich 
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DNA sequence in the center of the DNA target fragment may have been the source of the 
bend.  Previous researchers have noted that A-rich DNA sequences can bend.     
 Compounds 1 and 3, and to a lesser degree compound 2, lessened the intrinsic 
DNA bend of the DNA target (Table IV).  Complexes of the DNA and compounds 1 and 
3 displayed DNA bends of 25° and 29°, respectively, compared to 55° for the 
uncomplexed DNA.  Complexes of compound 2 lessened the intrinsic bend to 48°.   
 There are three possible mechanisms for how our compounds could have 
converted the intrinsic bend of the DNA into a more linear conformation (Fig. 42).  The 
 binding of the drug into the minor groove 
 
first is that these agents bind only to the linear conformation of DNA.  This would 
stabilize the linear DNA:drug complex which in turn would shift equilibrium to the linear 
complex resulting in a decreased FRET signal.  However, for this to occur, our 
compounds would have had to cause minor groove compression at the binding site (Fig. 
42A).  The presence of the phenyl ring of the compounds seems incompatible with a 
compression of the minor groove.  
 The second possibility is that the intrinsic bend observed in our target DNA is due 
to induced minor groove compression, where
results in widening the minor groove and straightening the DNA (Fig. 42B).  This 
mechanism would be consistent with the observation of minor groove compression in 
intrinsic bends and would also be compatible with our proposed mechanism of action for 
our agents.  Such a conclusion would have to be validated by additional experiments to 
determine the mechanism of the intrinsic bend in our target DNA fragments and also a 
more detailed study of different steric groups in the compounds. 
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A 
B 
 
ents may have occurred at a location other than the binding site of compounds 1, 2 
C 
Figure 42.  Our compounds could straighten the intrinsically bent 19-bp FRET DNA 
target by narrowing a widened minor groove (A), by widening a narrowed minor groove 
(B) or by creating a second, opposing, bend in the DNA at a different position from the 
intrinsic bend (C).  θ represents the bend angle of the DNA target in the absence of 
compound, the red arrow indicates where the compound binds to the DNA and θ' 
represents the closer to linear bend angle of the DNA target coupled to compound. 
 
 The third possible mechanism is that the intrinsic bends of the DNA target
θ
fragm
θ’ θ 
θ’ θ 
θ’ 
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and 3 (Fig. 42C).  This model would be especially likely in the event of the intrinsic bend 
occurring at a location other than the AT-rich central sequence.  In this situation, the end-
to-end distance of the DNA fragment was lengthened by the compound-induced second 
bend in the opposite direction as the intrinsic bend (Fig 42C).   The calculations of the 
magnitude of the bends induced by our compounds in this model are far more complex 
and would require numerous other experiments. 
The goal of this project was to create small molecules able to selectively bind to a 
DNA sequence and induce a DNA bend upon binding.  Using the polyamide netropsin as 
a parent compound we synthesized three compounds that combined the sequence-
selective binding of netropsin-related compounds and a DNA bending mechanism similar 
to that of ET-743.  Our compounds displayed a preference for AT-rich sequences, though 
 lacked the binding affinity of netropsin toward this sequence.  The conformation of 
DNA, as measured by the end-to-end distance of the DNA target changed when the 
compounds were bound to DNA.  This suggests that our agents have the ability to alter 
the conformation of DNA.  However, this alteration was more complex than expected.  
The DNA target possessed an intrinsic bend that was straightened when compounds 1, 2 
and 3 were bound.  This may have been accomplished through the DNA bending activity 
of the compounds, with bends induced counter to the intrinsic bends already present.  In 
they
this situation our compounds functioned as intended; compounds 1, 2 and 3 were able to 
selectively bind to a DNA target and induce a DNA bend upon binding. 
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V. MATERIALS & METHODS 
iego, CA).  The oligonucleotides were 
purified
 
 
V.A. Project 1: Tethered-TFOs and Gene Expression 
Chemicals and Enzymes.  The deoxynucleotides and linker phosphoramidites were 
purchased from Glen Research.  The unbroken TFOs, STFO and LTFO (Fig. 45), were 
purchased from TriLink Biotechnologies (San D
 by extraction from a polyacrylamide gel.  Restriction endonucleases, T4 
polynucleotide kinase, Quick T4 DNA ligase, Taq DNA polymerase and pBR322 were 
purchased from New England BioLabs (Ipswich, MA).  The EcoPro T7 kit was 
purchased from Novagen (San Diego, CA).  Recombinant firefly luciferase was 
purchased from Calbiochem (San Diego, CA).  The β-galactosidase was from Sigma-
Aldrich.  The anti-luciferase-HRP conjugated antibodies and the anti-β-galactodidase-
HRP-labeled antibodies were from Research Diagnostics, Inc. (Concord, MA). 
 
Oligonucleotide Syntheses.  The tethered-TFOs, STFO and LTFO, the broken TFOs, 
bSTFO and bLTFO (Fig. 43), the PCR primers (Fig. 43) and the oligonucleotides used to 
construct the plasmid inserts (Fig. 44 and 45) were synthesized on a PerSeptive 
Biosystems Expedite Nucleic Acid Synthesis System using standard conditions.  The 
oligonucleotides were purified by 13% denaturing PAGE followed by solid phase 
extraction. 
91 
A 
 
STFO: 5’-GGTGGGGTGGGTGGG-PgPgPg-GGGTGGGTGGGGTGG-3’ 
LTFO: 5’-GGTGGGGTGGGTGGG-TgTgTgTg-GGGTGGGTGGGGTGG-3’ 
GGTGG-3’ 
GGGGTGG-3’ 
 
 
 
phosphodiester unit, while Tg represents a triethylene glycol phosphodiester unit. (B) 
 
Plasmid Insert Construction.  The plasmid inserts (Fig. 44) were synthesized in four 
parts (Fig. 45) as described below.  Each oligonucleotide (100 pmol) was treated with T4 
polynucleotide kinase (10 units) at 37°C for 1h and the four oligonucleotides for each 
insert were combined, annealed by a heating-cooling cycle of 95°C for 5 min followed by 
slow cooling to 25°C at a rate of 1°C/min.  The plasmid inserts were ligated into whole 
units by treatment with Quick T4 DNA ligase (10 units) at room temperature for 5 min. 
 
Plasmid Construction. The plasmids were digested with restriction enzymes 
corresponding to the plasmid insert to be incorporated.  The cut plasmids were purified 
on an agarose gel.  The cut plasmid (50 ng) and the plasmid insert (5x the molarity of the 
cut plasmid) were ligated together with Quick T4 DNA ligase (10 units) at room 
temperature for 5 minutes.  Ligated plasmids were then amplified by transformation of 
DH5α E. coli cells cultured on ampicillin containing agar plates.  The colonies were then 
grown overnight via inoculation into ampicillin containing LB media.  Minipreps of the 
inoculations were performed to acquire the amplified plasmid DNA.  pBend was 
bSTFO:5’-GGTGGGGTGGGTGGG-3’ and 5’-PgPgPg-GGGTGGGTGG
bLTFO:5’-GGTGGGGTGGGTGGG-3’ and 5’-TgTgTgTg-GGGTGGGT
B 
C1:5’-CTAGCTAGCTAGTAGGAGGG-3’ 
C2:5’-CGCGGATCCAGATCTGCTCG-3’ 
E1:5’-CGTGCTGCTAGCTAGT-3’ 
E2:5’-TGTAGGAGCTATAGGC-3’   
Figure 43.  (A) The TFOs used in the assays.  Pg represents a propylene glycol 
Sequences of PCR primers C1, C2, E1 and E2. 
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constructed by inserting the TFO target DNA fragment (Fig. 44 and 45) into the 
XhoI digestive analysis.  
 the BglII/SalI site of pBend to create pBP77.  pBP77 was verified by XbaI digestive 
nstructed by inserting the luciferase gene of pGL3 
te of pBP77.  Insertion was verified by digestive analysis.  
 pBP83.  pBP83 was verified by XbaI 
digestive analysis.  The pBLP83 was constructed by inserting the luciferase gene of 
pGL3 into the NcoI/XbaI site of pBP83.  Insertion was verified by digestive analysis. 
pBLP80 was constructed by inserting the Phase 80 DNA fragment (Fig. 44 and 45), first 
cut with XhoI and NcoI, into the XhoI/NcoI site of pBLP83.  Insertion was verified by 
KpnI and BamHI digestive analysis. pBLP86 was constructed by inserting the Phase 86 
DNA fragment (Fig. 44 and 45) , first cut with XhoI and NcoI, into the XhoI/NcoI site of 
pBLP83.  Insertion was verified by KpnI and BamHI digestive analysis. 
 
 
 
 
 
 
 
 
NheI/B d by amHI site of pBR322.  Insertion was confirme
pBLP77 was constructed by first inserting the promoter DNA fragment (Fig. 44 and 45) 
into
analysis.  The pBLP77 was co
(Promega) into the NcoI/XbaI si
pBLP83 was constructed by first inserting the promoter DNA fragment (Fig. 44 and 45) 
into the BamHI/SalI site of pBend to create
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A 
   Nhe I                                              Xho I  BglII BamH I 
5’-CTAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCAGATCTG    -3’ 
3’-    GATCATCCTCCCCTCCCTCCCGCGGCCGCGCCCTCCCTCCCCTCCACGAGCTCGTCTAGACCTAG-5’ 
 
 
Bgl II-BamH I                                  Nco I Xba I Sal I 
B 
5’-GATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGTCTAGAG    -3’ 
3’-    GATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCAGATCTCAGCT-5’ 
C 
        Xho I    Kpn I                                          Nco I 
 
5’-CCGTCCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’ 
3’-GGCAGGAGCTCGTACCATGGGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’ 
D 
 
        Xho I    Kpn I                                            Nco I 
5’-CCGTCCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’ 
3’-GGCAGGAGCTCGTAGCCATGGTAGCTGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’ 
 
Figure 44. (A) The TFO target fragment sequence.  The Nhe I overhang is highlighted in 
yellow; the tethered-TFO target sites are in red text with the center of the bending region 
highlighted red; the Xho I site is highlighted in green; the Bgl II site is highlighted in 
pink; and the BamH I overhang is highlighted in blue.  (B) The promoter fragment 
sequence. The Bgl II/BamH I compatible overhang is highlighted in
promoter region is underlined with the -10 region highlighted in gray an
 blue; the malT 
d the -35 region 
ighlighted in yellow; the Nco I site is highlighted in red; the Xba I site is white text 
ighlighted in dark green; and the Sal I overhang is highlighted in black with white text.  
C) The Phase 80 fragment sequence. The Xho I site is highlighted in green; the Kpn I 
ite is white text highlighted with purple; the malT promoter region is underlined with the 
10 region highlighted in gray and the -35 region highlighted in yellow; and the Nco I site 
 highlighted in red.  (D) The Phase 86 fragment sequence. The Xho I site is highlighted 
 green; the Kpn I site is white text highlighted with purple; the malT promoter region is 
nderlined with the -10 region highlighted in gray and the -35 region highlighted in 
ellow; and the Nco I site is highlighted in red. 
h
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FO Target DNA Fragment: T
 
5’-
3’-
CTAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCGCGGGAGGGAGGGGAGGTGCTCGAGCAGATCTG    -3’ 
    GATCATCCTCCCCTCCCTCCCGCGGCCGCGCCCTCCCTCCCCTCCACGAGCTCGTCTAGACCTAG-5’ 
t4: 5’-GGCGCCCTCCCTCCCCTCCTACTAG-3’ 
e-stranded oligonucleotides to create promoter fragment: 
 5’-GATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACC-3’ 
hase 80 DNA Fragment: 
igure 45.  pBLP plasmid inserts. 
 
Single-stranded oligonucleotides to create TFO-target fragment: 
TFOt1: 5’-CTAGCTAGTAGGAGGGGAGGGAGGGCGCCGGCCCGGGAGG-3’ 
TFOt2: 5’-GAGGGGAGGTGCTCGAGCAGATCTG-3’ 
FOt3: 5’-GATCCAGATCTGCTCGAGCACCTCCCCTCCCTCCCGCGCC-3’ T
TFO
 
Promoter DNA Fragment: 
 
5’-GATCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGTCTAGAG    -3’ 
3’-    GATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCAGATCTCAGCT-5’ 
 
Singl
TT1:
TT2: 5’-TTATAACCATGGTCTAGAG-3' 
TT3: 5’-TCGACTCTAGACCATGGTTATAAGGTCGGCCAGAAACC-3’ 
TT4: 5’-TTTCTAATGCAAGCGTATAG-3’ 
 
P
 
5’-CCGTCCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’ 
3’-GGCAGGAGCTCGTACCATGGGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’ 
 
Single-stranded oligonucleotides to create Phase 80  fragment: 
P84a: 5’-CCGTCCTCGAGCATGGTACCCTATACGCTTGCATTAGAAAG-3’ 
P84b: 5’-GTTTCTGGCCGACCTTATAACCATGGCATG-3’ 
P84c: 5’-CATGCCATGGTTATAAGGTCGGCCAGAAACCTTTCTAATGCAAGC-3’ 
P84d: 5’-GTATAGGGTACCATGCTCGAGCACGG-3’ 
 
Phase 86 DNA Fragment: 
 
5’-CCGTCCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAGGTTTCTGGCCGACCTTATAACCATGGCATG-3’ 
3’-GGCAGGAGCTCGTAGCCATGGTAGCTGATATGCGAACGTAATCTTTCCAAAGACCGGCTGGAATATTGGTACCGTAC-5’ 
 
Single-stranded oligonucleotides to create Phase 86  fragment: 
P90a: 5’-CCGTCCTCGAGCATCGGTACCATCGACTATACGCTTGCATTAGAAAG-3’ 
P90b: 5’-GTTTCTGGCCGACCTTATAACCATGGCATG-3’ 
P90c: 5’-CATGCCATGGTTATAAGGTCGGCCAGAAACCTTTCTAATGCAAGC-3’ 
P90d: 5’-GTATAGTCGATGGTACCGATGCTCGAGCACGG-3’ 
 
F
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Gel Mobility Assay.  Two 129 bp DNA fragments, containing the TFO-target sequence, 
ere amplified by PCR from pBend using primers C1 and C2 to generate the centered 
FO target fragment or E1 and E2 to generate the end-located TFO target fragment.  The 
ragment was purified by 13% denaturing PAGE followed by extraction from the gel.  
cubated 
M MgCl2 and 10% sucrose at 
nondenaturing PAGE 
2.  The gel was run in 89 mM Tris borate 
 SYBR GOLD 
 imaged on a Kodak Digital Science Image 
LP86 
smids (2.7 nM ) were incubated with excess 
l2 and 10% sucrose at 37°C 
on and translation of the plasmid-TFO complexes was performed 
 
actosidase (200 ng) was 
buffer was added to each 
denatured in a thermocycler by incubation at 90°C for 
10 min. If the sample was not blue after the addition of the SDS-PAGE loading buffer, 1 
μL increments of 1 M Tris (pH 9.5) were added until a blue color was attained.  The 
samples were run by SDS-PAGE on 10% Tris-HCl Ready Gels (Bio-Rad Laboratories) in 
w
T
f
The purified centered and end-located TFO target fragments (2 pmol) were in
with TFOs (2pmol) in 10 mM Tris-HCl (pH 7.5), 10 m
37°C for 16h.  The TFO-target complexes were analyzed by 8% 
(29:1 cross-linking) containing 10 mM MgCl
and 10 mM MgCl2 buffer (TBM) for 4 h at 10 V/cm and stained with
(Molecular Probes) for 45 min.  The gel was
Station. 
 
Gene Expression Analysis.  The plasmids pBLP77, pBLP80, pBLP83, and pB
were linearized with NdeI.  The linearized pla
TFOs (0.27 μM)  in 10 mM Tris-HCl (pH 7.5), 10 mM MgC
for 16 h.  Transcripti
with the EcoPro T7 System (Novagen) and incubation for 1 h at 37°C.  A sample of the
expressed luciferase protein (10 μl) was removed and β-gal
added to each sample as a standard.  SDS-PAGE loading 
sample and the samples were then 
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a 25 mM Tris, 250 mM glycine and 0.1% SDS buffer at 33V/cm for 40 min.  The 
proteins were transferred from the gel to PVDF membranes in 25 mM Tris, 190 mM 
glycine, 20% methanol and 0.1% SDS at 100 V for 1h.  The membranes were blocked in 
PBS buffer (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4•7H2O, 1.4 mM KH2PO4) 
containing 10% nonfat milk at 4°C with rocking for 16 h and then washed in a wash 
buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA and 0.1% Tween-20).  The PVDF 
membranes were blotted with rabbit-derived anti-β-galactosidase-HRP conjugated 
antibodies (1:5000 from a 10 mg/mL stock) and goat-derived anti-luciferas-HRP 
conjugated antibodies (1:2000 for a 10 mg/mL stock) in a blotting buffer (100 mM NaCl, 
10 mM Tris, 1 mM EDTA, 0.1% Tween-20 and 1% nonfat milk) at 4°C with rocking for 
2 h.  The membranes were then washed with the wash buffer and treated with an ECL 
estern blotting kit (Amersham Biosciences) for 1 min.  The membranes were scanned 
V.B. Project 2: A Sequence Selective Push Bender 
 
Synthesis 2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic 
W
on a Kodak Digital Science Image Station with a 30 min exposure without UV light or a 
filter.  The image was analyzed with Kodak 1D Image Analysis software. 
 
 
acid (3-dimethylamino-propyl)-amide (1). 
2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid 
ethyl ester (4).  N-methylpyrrole-2-carboxylic acid (0.5 g; 4 mmol) and ethyl-2-amino-4-
phenyl-5-thiazole carboxylate (1 g; 4 mmol) were dissolved, by stirring, into DMF (20 
97 
mL).  EDCI (3 g; 16 mmol) and DMAP (2.44 g; 20 mmol) were added and the reaction 
mixture was stirred overnight at room temperature.  Ethyl acetate (200 mL) was added to 
the reaction mixture and the reaction mixture was then washed with 10% aqueous 
hydrochloric acid (3 x 200 mL) and saturated aqueous sodium bicarbonate (3 x 200 mL).  
The organic layer was collected, dried with magnesium sulfate and was rotavapped to 
dryness.  The resulting product was dried overnight under reduced pressure in the 
presence of P2O5.  Yield 61.6% (0.875 g; 2.46 mmol).  1H NMR 300 MHz (DMSO-d6) 
1.19-1.24 (3H, t, J = 6.6 Hz), 3.93 (3H, s), 4.15-4.22 (2H, q, J = 7.1 Hz), 6.15 (1H, s), 
7.05 (1H, s), 7.18 (1H, s), 7.43 (2H, s), 7.71 (2H, s),12.62 (1H, s). 
 
2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid 
(5).  2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid 
ethyl ester, 4 (0.3123 g; 0.879 mmol) was dissolved in a solution containing 1N lithium 
hydroxide (21.66 mL) and methanol (29.06 mL).  The reaction mixture was heated to 
0°C for 2.5 hours.  The reaction mixture was evaporated to half the original volume and  
thyl acetate (75 mL) was added.  The aqueous layer was removed and acidified with 
concentrated hydrochloric acid until the pH reached 3.  The acidic solution was then 
extracted with ethyl acetate (4 x 75 mL).  The organic layers were collected, dried with 
magnesium sulfate and filtered.  The filtrate was rotavapped to dryness.  The resulting 
product was dried overnight under reduced pressure in the presence of P2O5.  Yield 
74.8% (0.2034 g; 0.657 mmol).  H NMR 300 MHz (DMSO-d6) 3.93 (3H, s), 6.14 (1H, 
s), 6.71 (1H, s), 6.94 (1H, s), 7.17 (1H, s), 7.36-7.42 (2H, t, J = 8.79 Hz), 7.72-7.73 (2H, 
6
e
1
d, J = 3.93 Hz), 11.70 (1H, s), 12.53 (1H, s). 
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2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid (3-
dimethylamino-propyl)-amide (1).  2-[(1-Methyl-1H-pyrrole-2-carbonyl)-amino]-4-
phenyl-thiazole-5-carboxylic acid, 5 (0.03 g; 0.916 mmol) was dissolved in DMF (4 mL).  
HBTU (0.086 g; 0.366 mmol) and NMM (0.037 g; 0.366 mmol) were added to the 
reaction and the reaction mixture was stirred at room temperaturefor 2 hrs.  3-
(dimethylamino) propylamine (0.028 g; 0.275 mmol) was then added and the reaction 
mixture was stirred overnight at room temperature.  Ethyl acetate (15 mL) was added to 
the reaction mixture and the reaction mixture was washed with water (3 x 15 mL).  The 
organic layer was collected, dried with magnesium sulfate and filtered.  The filtrate was 
tavapped to dryness and purified using silica gel column chromatography using 5:1:0.2 ro
ethyl acetate:methanol:triethylamine.  Yield 51.3%   (0.019 g; 0.047 mmol).  1H NMR 
300 MHz (DMSO-d6) 1.65-1.72 (2H, quintet, J = 5.13 Hz), 2.42 (6H, s), 2.49 (1H, s), 
2.58-2.62 (2H, t, J = 6.86 Hz), 3.19-3.21 (2H, t, J = 5.31 Hz), 3.82 (3H, s), 6.14 (1H, s), 
7.15 (1H, s), 7.41-7.43 (2H, t, J = 6.81 Hz), 7.70-7.72 (2H, d, J = 7.06 Hz), 8.20 (1H, s).  
Anal. Calc for C21H25N5O2S.DMF: C 59.61; H 6.46; O 9.93 Found: C 59.11; H 6.02; O 
9.33. 
 
Synthesis {5-[5-(3-Dimethylamino-propylcarbamoyl)-4-phenyl-thiazol-2-ylcarbamoyl]-
1-methyl-1H-pyrrol-3-yl}-carbamic acid tert-butyl ester (2). 
2-[(4-tert-Butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-
thiazole-5-carboxylic acid ethyl ester (6).  4-tert-Butoxycarbonylamino-1-methyl-1H-
pyrrole-2-carboxylic acid (0.96 g; 4 mmol) from Sigma-Aldrich (St. Louis, MO) and 
ethyl-2-amino-4-phenyl-5-thiazole carboxylate (1 g; 4 mmol) were dissolved, by stirring, 
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into DMF (20 mL).  EDCI (3 g; 16 mmol) and DMAP (2.44 g; 20 mmol) were added to 
the mixture and the reaction was stirred overnight at room temperature.  Ethyl acetate 
(200 mL) was then added and the organc layer was then washed with 10% aqueous 
hydrochloric acid (3 x 200 mL) and saturated aqueous sodium bicarbonate (3 x 200 mL).  
The organic layer was collected, dried with magnesium sulfate and filtered.  The filtrate 
was rotavapped to dryness.    Yield 51.8% (0.982 g; 2.09 mmol).  1H NMR 300 MHz 
(DMSO-d6) 1.19-1.24 (3H, t, J = 7.07 Hz), 1.45 (9H, s), 3.87 (3H, s), 4.15-4.22 (2H, q, J 
= 6.72 Hz), 7.17 (1H, s), 7.25 (1H, s), 7.31 (1H, s), 7.40-7.45 (2H, t, J = 7.53 Hz), 7.71-
7.73 (2H, d, J = 7.08 Hz), 12.67 (1H, s). 
 
2-[(4-tert-Butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-
thiazole-5-carboxylic acid (7).  2-[(4-tert-Butoxycarbonylamino-1-methyl-1H-pyrrole-2-
carbonyl)-amino]-4-phenyl-thiazole-5-carboxylic acid ethyl ester, 6 (0.9824 g; 2.09 
mmol) was dissolved into a solution containing 1N lithium hydroxide (51.47 mL) and 
methanol (69.04 mL).  The reaction mixture was heated to 60°C for 3 hours, cooled and 
evaporated to half the original volume.  The resulting solution was extracted with ethyl 
cetate (175 mL) and the aqueous layer of the extraction was acidified with concentrated 
ith magnesium sulfate and 
a
hydrochloric acid to pH 3.  The acidic aqueous layer was then extracted with ethyl acetate 
(4 x 175 mL), the organic layers were collected, dried w
filtered.  The filtrate was rotavapped to dryness.  Yield 71.9% (0.665 g; 1.51 mmol).  1H 
NMR 300 MHz (DMSO-d6) 1.45 (9H, s), 3.87 (3H, s), 7.04 (1H, s), 7.16 (1H, s), 7.35 
(2H, s), 7.71-7.73 (2H, d, J = 4.14 Hz), 9.05 (1H, s), 9.21 (1H, s), 12.57 (1H, s). 
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{5-[5-(3-Dimethylamino-propylcarbamoyl)-4-phenyl-thiazol-2-ylcarbamoyl]-1-
methyl-1H-pyrrol-3-yl}-carbamic acid tert-butyl ester (2).  2-[(4-tert-
butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-
carboxylic acid, 7 (0.03 g; 0.068 mmol) was dissolved in DMF (4 mL).  HBTU (0.064 g; 
0.272 mmol) and NMM (0.028 g; 0.272 mmol) were added to the reaction.  The reaction 
mixture stirred at room temperature for 2 hrs followed by the addition of 3-
(dimethylamino) propylamine (0.021 g; 0.203 mmol).  The reaction mixture was stirred 
overnight at room temperature followed by addition of  ethyl acetate (15 mL) to the 
reaction mixture.  The organic layer was washed with water (3 x 15 mL), collected, dried 
ith magnesium sulfate and filtered.  The filtrate was rotavapped to dryness and the w
resulting product was purified by silica gel column chromatography using 5:1:0.2 ethyl 
acetate:methanol:triethylamine.  Yield 60.3%  (0.022 g; 0.041 mmol).  1H NMR 300 
MHz (DMSO-d6) 1.46 (9H, s), 1.53-1.57 (2H, t, J = 6.21 Hz), 2.08 (6H, s), 2.13-2.19 
(2H, quintet, J = 4.65 Hz), 3.17-3.19 (2H, t, J = 5.62 Hz), 3.87 (3H, s), 7.14 (1H, s), 7.20 
(1H, s), 7.40-7.42 (2H, d, J = 7.22 Hz), 7.69-7.72 (2H, d, J = 6.69 Hz), 8.09 (1H, s), 9.18 
(1H, s).  Anal. Calc for C26H34N6O4S.DMF: C 59.30; H 6.51; O 12.15 Found: C 58.99; H 
6.33; O 12.47. 
 
Synthesis of 2-[(4-Formylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-
thiazole-5-carboxylic acid (3-dimethylamino-propyl)-amide (3). 
2-[(4-Formylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-4-phenyl-thiazole-5-
carboxylic acid (3-dimethylamino-propyl)-amide (3).  {5-[5-(3-Dimethylamino-
ropylcarbamoyl)-4-phenyl-thiazol-2-ylcarbamoyl]-1-methyl-1H-pyrrol-3-yl}-carbamic p
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acid tert-butyl ester, 2 (0.070 g; 0.133 mmol) was dissolved in dichloromethane (5
Trifluoroacetic acid (0.3 mL) and benzenethiol (0.1 mL) were added and the reaction 
mixture was stirred at room temperature for 1 hour.  The reaction was rotavapped
dryness and the residue was washed with diethyl ether (3 x 15 mL) to remove non-polar 
impurities.  The residue was dissolved in ethanol (10 mL) and ethyl formate (20 mL) was 
added.  The reaction was heated to reflux for 48 hours, cooled and evaporated to dryness. 
The resulting residue was then purified by silica gel column chromatography using 
5:1:0.2 ethyl acetate:methanol:triethylamine.  Yield 73.4% (0.044 g; 0.098 mmol).  
 mL).  
 to 
 
ium bromide (4.4 μM final concentration) was added to a quartz cuvette 
ontaining Tris buffer (0.1 M Tris, 0.1 M NaCl, pH 8).  The fluorescence was measured 
d.  Compounds 1, 2 and 
ry 
1H 
NMR 300 MHz (DMSO-d6) 1.72-1.81 (2H, quintet, J = 5.43 Hz), 2.64 (6H, s), 2.84-2.90 
(2H, t, J = 8.28 Hz), 3.07-3.09 (2H, t,  J = 6.87 Hz), 3.90 (3H, s), 7.33 (1H, s), 7.41-7.45 
(2H, d, J = 9.21 Hz), 7.70-7.72 (2H, d, J = 6.33 Hz), 8.14 (1H, s), 8.24 (1H, s), 10.17 
(1H, s).  Anal. Calc for C22H26N6O3S.CH3CH2OH: C 57.58; H 6.44; O 12.78 Found: C 
58.01; H 6.12; O 12.50. 
 
Ethidium bromide displacement assay.  This assay was performed on a Perkins Elmer 
L555 Fluorimeter equipped with FL WinLab software.  The assay was conducted as 
follows.  Ethid
c
(ex. 545 nm, em. 595 nm).  The DNA target of interest was added (8.8 μM in DNA base 
pairs final concentration) and the fluorescence was again measure
3 were then titrated into the cuvette, measuring the fluorescence 5 min after eve
addition.  Each compound was titrated until the relative fluorescence had decreased to 
less than 50%. 
102 
 FRET analysis.  Two 19-bp DNA targets were diluted to 0.5 μM in 10 mM sodium 
phosphate buffer (pH 7).  One duplex contained a 5’-terminal fluorescein, while the other 
duplex contained both a 5’-terminal fluorescein and a terminal tetramethylrhodamine on 
the other strand.  The emission spectrum for each of these duplexes was analyzed in both 
the absence and presence of compounds 1, 2 and 3.  The samples were analyzed on a 
PerkinElmer Instruments LS55 Luminescence Spectrometer with corresponding FL 
WinLab software.  The excitation and emission slits of the machine were set to 3 nm and 
10 nm, respectively.  The samples were excited at 495 nm and the emissions were 
scanned from 500 nm to 700 nm.  Data analysis utilized the integrated area under of the 
various spectrums from 510 nm to 530 nm as calculated with the FL WinLab software.  
The emission spectrums for 1 ml of each DNA target, at 0.5 μM in a quartz cuvette, were 
first scanned without any of the synthesized compounds present.  The samples were then 
anned after the addition of compounds 1, 2 and 3, in excess at 2.0 μM, and a 15 minute sc
incubation period at room temperature. 
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VI. 1H-NMR Spectra 
Figure 46.  1H-NMR Spectrum of compound 1 in DMSO-d6. 
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 Figure 47.  1H-NMR Spectrum of compound 2 in DMSO-d6. 
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 Figure 48.  1H-NMR Spectrum of compound 3 in DMSO-d6. 
 
106 
 Figure 49.  1H-NMR Spectrum of compound 4 in DMSO-d6. 
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 Figure 50.  1H-NMR Spectrum of compound 5 in DMSO-d6. 
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 Figure 51.  1H-NMR Spectrum of compound 6 in DMSO-d6. 
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 Figure 52.  1H-NMR Spectrum of compound 7 in DMSO-d6. 
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VII. Appendix A: Statistical Difference in Percent Change in Luciferase Expression 
Table V.  Significant Difference between the Percent Change in Luciferase Expression 
Levels Caused by the Various Tethered-TFOs for Individual pBLP Plasmids at a 95% 
Confidence Level 
    none STFO LTFO bSTFO bLTFO 
  none - Y Y N N 
 STFO Y - Y Y Y 
pBLP77 LTFO Y Y - N N 
 bSTFO N Y N - N 
 bLTFO N Y N N - 
- Y N N N   none 
 STFO Y - Y Y Y 
pBLP80 LTFO N Y - N N 
 bSTFO N Y N - N 
N Y N N -   bLTFO 
 none - Y Y Y N 
 STFO Y - Y Y Y 
pBLP83 LTFO Y Y - N N 
 bSTFO Y Y N - N 
N Y N N -   bLTFO 
 none - Y N N N 
 STFO Y - Y Y Y 
pBLP86 LTFO N Y - N N 
 bSTFO N Y N - N 
 bLTFO N Y N N -  
Y = Yes; significant difference in the change in expression levels with 95% confidence 
N = No; there was no significant difference 
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Table VI.  Significant Difference between the Percent Change in Luciferase Expression 
Level 
Levels Between the pBLP Plasmids for the Various Tethered-TFOs at a 95% Confidence 
    pBLP77 pBLP80 pBLP83 pBLP86 
STFO pBLP77 - Y Y N 
 pBLP80 Y - Y Y 
 pBLP8 Y Y - Y 3
N Y Y -  pBLP86
LTFO pBLP77 - N Y N 
N - N N  pBLP80
 pBLP83 Y N - N 
N N N -   P86pBL
bSTFO pBLP77 - N Y N 
N - N N  pBLP80
 pBLP83 Y N - N 
N N N -   P86pBL
- N N N bLTFO pBLP77
N - N N  pBLP80
N N - N  pBLP83
N N N -  pBLP86 
Y = Yes; sign cant e in  chang  expres n level ith 95% onfidence 
N = No; there as no ant d erence 
 
ifi differenc  the e in sio s w  c
 w  signific iff
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VIII. Appendix B: Reaction Mechanisms 
VIII.A. Amide bond formation of Compounds 4 and 6 in Schemes I a
 
Condensation of N ethylpyrrole-2-carboxylic acid (where R was a proton, H) or 4-tert-
butoxycarbonylami o-1-m -py le-2-carboxylic acid (where R was –NHBoc) 
and ethyl-2-amino-4-phenyl-5-thiazole carboxylate with EDCI and DMAP, to form 4 or 
6, schemes I and II
nd II 
-m
n ethyl-1H rro
. 
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VIII.B. C-terminal ester hydrolysis to form 5 and 7 in Schemes I and II 
 
 Hydrolysis of C-terminal esters of compounds 4 and 6 with 1N LiOH to generate free
carboxylic acid, compounds 5 and 7, schemes I and II. 
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VIII.C. Addition of C-terminal tail to form 1 and 2 in Schemes I and II 
 
HBTU and NMM coupling conditions were used to form an amide bond between the C-
terminal carboxylic acids of compounds 5 and 7 and the primary amine of 3-
imethylamino)propylamine to form the final products, 1 and 2, schemes and II. (d
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VIII.D. Scheme III reactions 
VIII.D.1. Deprotection of N-terminal Boc group of compound 2 
 
Deprotection of Boc group of compound 2 with TFA and benzenethiol, as a carbocation 
scavenger, to yield a free amine at the N-terminus of the molecule, scheme III. 
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VIII.D.2. Ethyl formate reaction to form N-terminal formamide of 3 
as immediately reacted 
ith ethyl formate to generate the formamide, compound 3, scheme III. 
 
The N-terminal free amine generated by Boc group deprotection w
w
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